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Cellular/Molecular

Neuronal Glutamate Transporters Control Dopaminergic
Signaling and Compulsive Behaviors
X Stefania Bellini,1* X Kelsey E. Fleming,1* X Modhurika De,1* X John P. McCauley,1 X Maurice A. Petroccione,1
X Lianna Y. D’Brant,1 X Artem Tkachenko,1 X SoYoung Kwon,1,2 X Lindsey A. Jones,1 and X Annalisa Scimemi1
1

State University of New York, Albany, New York 12222, and 2Emma Willard School, 285 Pawling Ave, Troy, NY 12180

There is an ongoing debate on the contribution of the neuronal glutamate transporter EAAC1 to the onset of compulsive behaviors. Here,
we used behavioral, electrophysiological, molecular, and viral approaches in male and female mice to identify the molecular and cellular
mechanisms by which EAAC1 controls the execution of repeated motor behaviors. Our findings show that, in the striatum, a brain region
implicated with movement execution, EAAC1 limits group I metabotropic glutamate receptor (mGluRI) activation, facilitates D1 dopamine receptor (D1R) expression, and ensures long-term synaptic plasticity. Blocking mGluRI in slices from mice lacking EAAC1 restores
D1R expression and synaptic plasticity. Conversely, activation of intracellular signaling pathways coupled to mGluRI in D1R-containing
striatal neurons of mice expressing EAAC1 leads to reduced D1R protein level and increased stereotyped movement execution. These
findings identify new molecular mechanisms by which EAAC1 can shape glutamatergic and dopaminergic signals and control repeated
movement execution.
Key words: dopamine; glutamate; mGluR; striatum; synaptic transmission; transporter

Significance Statement
Genetic studies implicate Slc1a1, a gene encoding the neuronal glutamate transporter EAAC1, with obsessive-compulsive disorder
(OCD). EAAC1 is abundantly expressed in the striatum, a brain region that is hyperactive in OCD. What remains unknown is how
EAAC1 shapes synaptic function in the striatum. Our findings show that EAAC1 limits activation of metabotropic glutamate
receptors (mGluRIs) in the striatum and, by doing so, promotes D1 dopamine receptor (D1R) expression. Targeted activation of
signaling cascades coupled to mGluRIs in mice expressing EAAC1 reduces D1R expression and triggers repeated motor behaviors.
These findings provide new information on the molecular basis of OCD and suggest new avenues for its treatment.

Introduction
Persistent thoughts, anxiety, and repeated execution of stereotyped movements are hallmark features of neuropsychiatric disorders such as obsessive-compulsive disorder (OCD) (Kessler et
al., 2005). Family-based linkage analyses identify the gene Slc1a1,
which encodes the neuronal glutamate transporter EAAC1, as
one of the strongest candidate genes for OCD (Hanna et al., 2002;
Arnold et al., 2006; Dickel et al., 2006; Stewart et al., 2007; Shugart
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et al., 2009; Wendland et al., 2009; Samuels et al., 2011). Alternative isoforms of Slc1a1 that are differentially regulated in OCD
patients have been shown to impair glutamate uptake via EAAC1
(Porton et al., 2013). One of the hypotheses that has been put
forward is that loss of function of EAAC1 leads to increased
extracellular glutamate concentration and hyperactivity in the
brain (Porton et al., 2013). This hypothesis is not consistent with
functional studies in vitro indicating that regulation of the ambient glutamate concentration in the brain does not rely on neuronal but rather glial glutamate transporters (Jabaudon et al., 1999;
Cavelier and Attwell, 2005; Le Meur et al., 2007), which are ⬃100
times more abundantly expressed than neuronal transporters
(Holmseth et al., 2012). Our own previous work shows that
EAAC1 exerts a powerful control of phasic glutamatergic synaptic transmission, but does not alter the ambient glutamate
concentration in the hippocampus (Scimemi et al., 2009). Despite these findings, our knowledge on the function of EAAC1 in
regions of the brain that show structural and functional abnormalities in patients with OCD, such as the striatum, remains
limited.
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The striatum is the main entry point of excitatory inputs to
the basal ganglia and exerts a fundamental role in the control of
anxiety and movement execution (Piras et al., 2015). In the striatum, glial glutamate transporters clear synaptically released
glutamate from the extracellular space and regulate GluA/N activation, similar to what they do in the hippocampus (Goubard et
al., 2011). EAAC1 is abundantly expressed in the striatum, but its
role in regulating synaptic function has so far remained elusive
(Danbolt, 2001; Holmseth et al., 2012). Here, we show that loss of
EAAC1 is associated with increased stereotyped movement execution and anxiety-like behaviors in mice. In the striatum, EAAC1
limits group I metabotropic glutamate receptor (mGluRI) activation and, by doing so, promotes D1 dopamine receptor (D1R)
expression. Blocking mGluRIs in mice lacking EAAC1 and cellspecific activation of signaling cascades coupled to mGluRI in
mice expressing EAAC1 allow for bidirectional control of D1R
expression, synaptic plasticity, and repeated movement execution. These results identify new molecular mechanisms by which
EAAC1 controls the function of the striatum and point to its
pivotal role as a molecular switch controlling mGluRI activation,
glutamatergic and dopaminergic transmission, and ultimately
the execution of persistent motor behaviors.

Materials and Methods
Ethics statement
All experimental procedures were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee at
the State University of New York (SUNY)–Albany and guidelines described in the National Institutes of Health’s Guide for the Care and Use of
Laboratory Animals.

Mice
All mice were group housed and kept under a 12 h light cycle (7:00 A.M.
on, 7:00 P.M. off) with food and water available ad libitum. Constitutive
EAAC1 knock-out mice (EAAC1 ⫺/⫺) were obtained by targeted disruption of the Slc1a1 gene via insertion of a pgk neomycin resistance cassette
in exon 1 of the Slc1a1 gene, as originally described by Peghini et al. (1997).
EAAC1 ⫺/⫺ breeders were generated after back-crossing EAAC1 ⫹/⫺ mice
with C57BL/6 mice for ⬎10 generations, as described by Scimemi et al.
(2009). C57BL/6 wild-type (WT) and EAAC1 ⫺/⫺ mice at postnatal day 0
(P0) to P35 were identified by PCR analysis of genomic DNA. EAAC1 ⫺/⫺
mice develop normally during the first 5 weeks of postnatal life. They are
fertile and, although they give birth to smaller litters (number of pups in
each litter: WT 8.2 ⫾ 0.3 (n ⫽ 43), EAAC1 ⫺/⫺ 6.5 ⫾ 0.4 (n ⫽ 42), ***p ⫽
8.0e-4), the litters are as viable as those of WT mice ( perinatal mortality
rate: WT 0.23 ⫾ 0.04 (n ⫽ 40), EAAC1 ⫺/⫺ 0.30 ⫾ 0.06 (n ⫽ 41), p ⫽
0.30) and have a similar sex distribution ( proportion of females in each
litter: WT 0.47 ⫾ 0.04 (n ⫽ 32), EAAC1 ⫺/⫺ 0.51 ⫾ 0.03 (n ⫽ 26), p ⫽
0.52). These data are consistent with previous phenotypic characterization of EAAC1 ⫺/⫺ mice (Peghini et al., 1997).
D1 Cre/⫹ mice (RRID:MMRRC_030778-UCD; Stock Tg(Drd1cre)EY217Gsat/Mmucd) and A2A Cre/⫹ mice (RRID:MMRRC_036158UCD; Stock B6.FVB(Cg)-Tg(Adora2a-cre)KG139Gsat/Mmucd) (Gong
et al., 2003; Gong et al., 2007) were kindly provided by Drs. A.V. Kravitz
and C.F. Gerfen (National Institute of Diabetes and Digestive and Kidney
Diseases –National Institutes of Health). In these mice, the protein Crerecombinase is expressed under the control of the promoter for D1Rs
and the adenosine receptor 2, which colocalizes with D2 dopamine receptors (D2Rs), respectively. Ai9 Tg/Tg conditional reporter mice [RRID:
IMSR_JAX:007909; Stock B6.Cg-Gt(ROSA)26Sor tm9(CAG-tdTomato)Hze;
Madisen et al., 2010] were kindly provided by Dr. P.E. Forni (SUNY–
Albany). D1 tdTomato/⫹ mice were purchased from The Jackson Laboratory [RRID:IMSR_JAX:016204; Stock Tg(Drd1a-tdTomato)6Calak].
Genotyping was performed on toe tissue samples of P7–P10 mice.
Briefly, tissue samples were digested at 55°C overnight in a lysis buffer
containing the following (in mM): 100 Tris base, pH 8, 5 EDTA, and 200
NaCl, along with 0.2% SDS and 100 g/ml proteinase K. DNA samples

Table 1. Sequence of primers used for PCR analysis
Gene

Primer forward

Band
size (bp)

Primer reverse

EAAC1 ⫹/⫹ 5’ AGAAGCTCCTCGGTGGGACAC 3’ 5’ GAGAGCAGCAGCCAGTGATTC 3’ 358
5’ GAGAGCAGCAGCCAGTGATTC 3’ 680
EAAC1 ⫺/⫺ 5’ CTGTGCTCGACGTTGTCACTG 3’
5’ GCTATGGAGATGCTCCTGATGGAA 3’ 5’ CGGCAAACGGACAGAAGCATT 3’ 340
D1 Cre/⫹
A2A Cre/⫹ 5’ CGTGAGAAAGCCTTTGGGAAGCT 3’ 5’ CGGCAAACGGACAGAAGCATT 3’ 350
5’ AAGGGAGCTGCAGTGGAGTA 3’
5’ CCGAAAATCTGTGGGAAGTC 3’ 297
Ai9 0/0
5’ CTGTTCCTGTACGGCATGG 3’
5’ GGCATTAAAGCAGCGTATCC 3’ 196
Ai9 Tg/0
5’ TTTCTGATTGAGAGCATTCG 3’ 750
D1 tdTomato/⫹ 5’ CTTCTGAGGCGGAAAGAACC 3’
Table 2. PCR protocol for EAAC1
Initiation/
melting Denaturation Annealing Elongation Amplification Hold
Temperature (°C) 95
Duration (min)
3
Cycles
1

95
0.5
34

63
0.5

72
1.5

72
10
1

4
⬁

Table 3. PCR protocol for D1 Cre/ⴙ and A2A Cre/ⴙ
Step

Initiation/
Melting Denaturation Annealing Elongation Amplification Hold

Temperature (°C) 94
Duration (min)
5
Cycles
1

94
65–55
72
0.25
0.5
0.17
40 (1–10: ⌬TAnneal ⫺ 1°C/cycle)

72
5
1

4
⬁

Table 4. PCR protocol for D1 tdTomato/ⴙ
Step

Initiation/
melting Denaturation Annealing Elongation Amplification Hold

Temperature (°C) 95
Duration (min)
3
Cycles
1

95
0.25
35

60
0.25

72
0.25

72
1
1

4
⬁

Table 5. PCR protocol for Ai9
Step

Initiation/
melting Denaturation Annealing Elongation Amplification Hold

Temperature (°C) 94
Duration (min)
2
Cycles
1

94
65– 60
72
0.33
0.25
0.17
38 (1–10: ⌬TAnneal ⫺ 0.5°C/cycle)

72
2
1

10
⬁

were diluted in nuclease-free water (500 ng/l) and processed for PCR
analysis. The PCR primers used for EAAC1, D1R Cre/⫹, A2A Cre/⫹,
D1 tdTomato/⫹, and Ai9 were purchased from Fisher Scientific and their
nucleotide sequence is listed in Table 1. The PCR protocol for EAAC1,
D1R Cre/⫹, A2A Cre/⫹, D1 tdTomato/⫹, and Ai9 are described in Tables 2, 3,
4, and 5. PCRs for D1 tdTomato/⫹ were performed using a Hotstart Taq
polymerase (catalog #KK5621; KAPA Biosystems). For all other reactions, we used standard TaqDNA Polymerase (catalog #R2523; Millipore
Sigma).

Behavior
Before performing any behavioral test, mice were acclimated to a new
behavioral suite for at least 30 min. All mice were tested between 9:00
A.M. and 1:00 P.M. A battery of behavioral tests was performed on
naive WT and EAAC1 ⫺/⫺ mice (P14 –P35) and on WT and D1 Cre/⫹ and
A2A Cre/⫹ mice subjected to AAV-hSyn-DIO-hM3D(Gq)-mCherry stereotaxic and clozapine-N-oxide (CNO) intraperitoneal injections according to the experimental design described in the Results. The battery
of behavioral tests included grooming, SmithKline-Beecham Harwell
Imperial-College and Royal-London-Hospital Phenotype Assessment
(SHIRPA), flying saucer, open-field, elevated plus maze, and marbleburying tests, performed as described below. Each behavioral apparatus
was cleaned with 70% ethanol between each test.
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Grooming test. The behavioral arena used to acquire videos for the
grooming analysis consisted of four chambers with clear bottom and
white sidewalls (L 15 cm ⫻ W 25 cm ⫻ H 15 cm). A digital SLR camera
(Canon EOS Rebel T3i with EF-S 18 –55 mm f/3.5–5.6 IS lens, 60 fps) was
positioned 15–30 cm below the grooming chamber to acquire 10-minlong videos in which we monitored the grooming behavior of each
mouse. The distance traveled by the forepaws during grooming was analyzed using M-Track, a newly developed tracking algorithm (Reeves et
al., 2016). The identification of the phase composition of each grooming
episode was performed according to the scaling system described by
Kalueff et al. (2007). Briefly, we identified phases in which there was no
grooming (Phase 0), paw licking (Phase 1), face wash (Phase 2), body
grooming (Phase 3), hind leg licking (Phase 4) and tail/genitals grooming
(Phase 5). Correct transitions between grooming phases include the progressive transitions through all the steps of a grooming syntactic chain
(e.g., 0 –1, 1–2, 2–3, 3– 4, 4 –5, and 5– 0). Any other transition that did not
follow this order was classified as incorrect (Kalueff et al., 2007).
SHIRPA test. The SHIRPA protocol is a collection of simple tests that
provide a standardized, high-throughput screen for assessing the phenotype of WT and EAAC1 ⫺/⫺ mice (P14 –P35) (Rogers et al., 1997; Rogers
et al., 1999). The SHIRPA test is effective in distinguishing qualitative
differences between different strains of mice. The following tests and
scores were included in the SHIRPA protocol.

(13) Forelimb place (0 –3; mouse is held by the tail on a hard surface
and a forelimb is gently moved out to the side using a cottontipped applicator; a normal response is to return the limb under
the body immediately): leg stays where placed (0), slow or incomplete return (1), promptly returns the leg to normal position
(2), hyperactive response (3).
(14) Withdrawal (0 –3; mouse is held by the tail on a hard surface and
the hindlimb is picked up and pulled out at a 45° angle until it is
stretched and then let go; a normal mouse rapidly returns the
hindlimb to normal position): leg drops to ground and does not
return to normal position (0), leg slow to return (1), rapid return
(2), hyperactive response (3).
(15) Biting (0 –1; a wooden stick is placed in front of the mouse’s
mouth; the most common reaction is to ignore or turn away
from the stick): no biting (0), biting (1).
(16) Clicker (hearing test; 0 –3; mouse is held by the tail base on a hard
surface and a clicker is used once after a moment of silence to
monitor for an ear flick or stop response): no response (0), difficulty in eliciting response (1), immediate response (2), abnormal response (3).
(17) Grip: mouse is placed on a wire metal grid 1–2 feet above ground,
a timer is started, the grid shaken gently, and then rapidly flipped
over. The time until the mouse falls off the grid is measured (in
seconds).

(1) Condition score (1–5): emaciated (1), thin (2), normal (3), overconditioned (4), and obese (5).
(2) Gait (0 –1; monitors exaggerated limb movements, dragging,
and uneven cadence): abnormal (0), normal (1).
(3) Posture: (0 –1; monitors the presence of rounded or hunched
body, head tilt, and tail dragging): abnormal (0), normal (1).
(4) Body tone (0 –3; mouse is held by the tail base on a hard surface
and gently pressed with two fingers over the mid-dorsum): flaccid (0), allows depression to the floor (1), allows some flattening
(2), hunches back to completely resist compression (3).
(5) Petting escape (0 –3; mouse is held by the tail base on a hard
surface and stroked down its flanks from front to back): no reaction (0), difficult to elicit escape response (1), easy to elicit
escape response (2), difficult to test because of spontaneous escape attempts (3).
(6) Passivity (0 –3; mouse is held by the tail and the front paws placed
on the edge of the cage top; normal mice promptly climb up to
the top of the cage; falling off or hanging without climbing is
abnormal): falls (0), delayed or unsuccessful attempt to climb up
(1), normal (2), hyperactive (3).
(7) Trunk curl (0 –3; mouse is suspended from the tail for 15 s and
monitored for curling of trunk): zero or abnormal response (e.g.,
hindlimb clasping) (0), curls ⬍90° (1), curls to 90° or more (2),
climbs up the tail (3).
(8) Righting (0 –3; one hand is used to hold the mouse by the tail base
and the other to provide a vertical surface; normal mice feel the
surface of the hand and quickly flip over): mouse does not right itself
(0), struggles to right itself (1), rights itself (2), hyperactive (3).
(9) Visual placing/reach touch (0 –1; mouse is held by the tail and
lowered slowly toward the cage lid): blind mice do not reach out
until forelimbs or whiskers touch (0), normal mice start to reach
toward the surface well before touching it (1).
(10) Whisker response (0 –3; vibrissae are stimulated using a cottontipped applicator; touching vibrissae should elicit a response,
including cessation of “whisking” or a subtle responsive nose
quiver): no response (0), response difficult to elicit (1), normal
response (2), hyperactive response (3).
(11) Ear twitch (0 –3; a cotton-tipped applicator is used to gently
touch the ear pinna; a normal response is a rapid ear twitch): no
response (0), difficult to elicit response (1), obvious response (2),
hyper-repetitive response (3).
(12) Palpebral reflex (0 –3; a cotton-tipped applicator is used to gently
touch the cornea): no reaction (0), slow blink (1), quick blink
(2), hyper-repetitive blinking (3).

Flying saucer (running wheel) test. A plastic flying saucer disk (A ⫽ 13
cm) connected to an odometer (Model #SD-548B; Shenzhen Sunding
Electron) was positioned in a standard rat cage. The distance and time
spent on the flying saucer were monitored over a period of 30 min.
Open-field test. In the open-field test, we monitored the position of a
mouse freely moving in a white Plexiglas box (L 46 cm ⫻ W 46 cm ⫻ H
38 cm). Each mouse was video monitored for 15 min using a Live! Cam
Sync HD webcam (Model #VF0770; Creative Labs). Videos were analyzed using AnyMaze (Stoelting).
Elevated plus maze test. The elevated plus maze consisted of 2 open and
2 closed arms (L 35.6 cm ⫻ W 5 cm) that extended from a center platform
(L 5 cm ⫻ W 5 cm) elevated 52 cm from the floor. Each mouse was placed
in the center area of the elevated plus maze facing an open arm and
allowed to move freely between the arms for 15 min. Each mouse was
video monitored for 15 min using a Live! Cam Sync HD webcam (Model
#VF0770; Creative Labs). Videos were analyzed using AnyMaze (Stoelting). The number of entries and the amount of time spent in the open and
closed arms were assessed as indices of anxiety-like behaviors.
Marble-burying test. A mouse cage was filled with 5 cm bedding material and on top of it were arranged 24 glass marbles (A ⫽ 0.6 cm) in a 4 ⫻
6 grid (distance from cage walls ⫽ 1.3 cm; distance between marbles ⫽
3.8 cm). Each mouse spent 30 min in this cage. At the end of this time, the
marbles that had ⱖ50% of their top surface covered with bedding material were counted.

Real-time quantitative PCR

Acute brain slices were prepared from WT and EAAC1 ⫺/⫺ mice of either
sex (P16 –P24), which were deeply anesthetized with isoflurane and decapitated in accordance with SUNY–Albany Animal Care and Use Committee guidelines. The brain was rapidly removed and placed in ice-cold
slicing solution bubbled with 95% O2/5% CO2 containing the following
(in mM): 119 NaCl, 2.5 KCl, 0.5 CaCl2, 1.3 MgSO4 䡠 H2O, 4 MgCl2, 26.2
NaHCO3, 1 NaH2PO4, and 22 glucose, 320 mOsm, pH 7.4. Coronal brain
slices (250 m thick) were prepared using a vibrating blade microtome
(VT1200S; Leica Microsystems). The slices were transferred to an icecold RNA stabilizing solution (catalog #76106; Qiagen) in which the
dorsolateral striatum (DLS) was separated from the ventromedial striatum (VMS). The total RNA was purified and transcribed into cDNA
using TaqDNA polymerase (catalog #201205; Qiagen) according to the
manufacturer’s instructions. We measured transcriptional levels of
Drd1a and Drd2 in triplicate samples using the TaqMan gene expression
assays (Thermo Fisher Scientific). Each PCR was run as a duplex reaction
using the housekeeping gene Hprt1 as an internal control. We used the
following primers to measure the amount of cDNA for Drd1a, Drd2 and
Hprt: Drd1a (catalog #Mm02620146_s1, FAM-MGB), Drd2 (catalog
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#Mm00438545_m1, FAM-MGB), Slc1a1 (catalog #Mm00436587_m1,
FAM-MGB), Hprt1 (catalog #Mm00446968_m1, VIC-MGB) (Thermo
Fisher Scientific). All reactions were either performed using the TaqMan
Universal Master Mix II (catalog #4440042; Thermo Fisher Scientific) or
nuclease-free water (Millipore catalog #W4502 Sigma). Initial validation
experiments were performed using a range of cDNA dilutions to ensure
similar amplification efficiency of all target cDNAs. A no-template
control (NTC) in which cDNA was omitted from the reaction mixture
was used to monitor contamination and primer– dimer formation that
could produce false-positive results. In each experiment, the threshold
cycle (CT) at which fluorescence from amplification exceeded the background fluorescence values was set within the exponential growth region
of the amplification curve. qRT-PCR data were analyzed using the comparative CT method as described by Schmittgen and Livak (2008). In each
sample, we calculated the difference between the CT values (⌬CT) for
Drd1a, Drd2, or Slc1a1 and the housekeeping gene Hprt. Then, we calculated the difference in the ⌬CT values between the test and NTC samples and
calculated 2 ⫺⌬CT. The ratio of these values was used to calculate the relative
expression of different genes in samples from WT and EAAC1 ⫺/⫺ mice (see
Fig. 6).

Fluorescence labeling and imaging

D1 Cre/⫹:Ai9 Tg/0, D1 tdTomato/⫹, A2A Cre/⫹:Ai9 Tg/0, D1 Cre/⫹:Ai9 Tg/0:
EAAC1 ⫺/⫺, D1 tdTomato/⫹:EAAC1 ⫺/⫺, and A2A Cre/⫹:Ai9 Tg/0:EAAC1 ⫺/⫺
mice (P21–P37) were deeply anesthetized with an intraperitoneal injection of pentobarbital (4 mg/g, w/w; catalog #54925-045-10; MedPharmex) and transcardially perfused with 20 ml of PBS 0.1 M and 20 ml
of 4% paraformaldehyde in PBS (4% PFA/PBS) at 4°C. The dissected
brains were postfixed overnight at 4°C in 4% PFA/PBS and cryoprotected
at 4°C in 30% sucrose/PBS. Coronal sections (40 m thick) were prepared using a vibrating blade microtome (VT1200S; Leica Microsystems). All sections were postfixed for 20 min at 4°C in 4% PFA/PBS.
Sections used for cell density measures were then washed in PBS and
mounted onto microscope slides using ProLong Gold anti-fade mounting medium (catalog #P36934; Thermo Fisher Scientific) or DAPI
Fluoromount-G (catalog #0100 –20; Southern Biotech). The sections
were then blocked and permeabilized for 1 h at room temperature (RT)
in a solution of PBS containing horse serum 10%, BSA 3%, and Triton
X-100 0.5%. The primary antibody incubation was performed by incubating the sections overnight at 4°C in a solution of PBS containing horse
serum 3%, BSA 1%, and Triton X-100 0.3% and one or more of the
following primary antibodies: polyclonal rabbit anti-D1- or D2 dopamine receptor (1:100, RRID:AB_2039826 and RRID:AB_2039828, respectively; Alomone Labs). The secondary antibody incubation was
performed for 2 h at RT using Alexa Fluor 488 goat anti-rabbit IgG
(RRID:AB_2576217; Thermo Fisher Scientific) diluted to 1:500 in 0.1%
Triton X-100/PBS. The brain sections were mounted onto microscope
slides using ProLong Gold antifade mountant (catalog #P36934, Thermo
Fisher Scientific) or DAPI Fluoromount-G (catalog #0100 –20; Southern
Biotech). Confocal images were acquired using a Zeiss LSM710 inverted
microscope equipped with 405 nm diode and 488 nm Ar and 561 nm
DPSS lasers. All images (1024 ⫻ 1024 pixels) were acquired using a 63⫻
oil-immersion objective (numerical aperture ⫽ 1.4) as averages of 16
consecutive images.
The image analysis was performed using Fiji software (https://fiji.sc/).
Cell density measures were obtained by counting the number of immunolabeled D1R- and D2R-expressing medium spiny neurons (D1- and
D2-MSNs, respectively) in matrix areas of the DLS and VMS. The proportion of D1- and D2-MSNs was calculated as the ratio of D1 Cre/⫹:
Ai9 Tg/0 or A2A Cre/⫹:Ai9 Tg/0 and the total number of cell nuclei labeled
with DAPI (data not shown). The n values reported in the text refer to the
number of mice used for these experiments. Data were collected from at
least three sections from each mouse.

Western blot
Western blot experiments were performed on protein extracts from the
striatum of WT and EAAC1 ⫺/⫺ mice of either sex (P21–P36). Membrane and cytoplasmic protein extracts were obtained using the MemPER Plus Membrane Protein Extraction Kit (catalog #89842; Thermo

Table 6. Initial conditions used in the 3D Monte Carlo model
Molecule name

No. of molecules

Concentration (M)

DARPP-32
CdK5
CK1
CK2
PDE
PP2A
PP2B (inactive)
PP2C
R2C2
Ca 2⫹

3,000
120
100
100
1,204
120
200
80
4,000
60

4.98
0.2
0.166
0.166
2
0.2
0.332
0.133
6.64
0.1

Fisher Scientific) according to the manufacturer’s instructions using
a mixture of protease and phosphatase inhibitors (10 l/ml, catalog
#78441; Thermo Fisher Scientific). The membrane protein extracts were
used to measure protein levels of D1R and D2R (see Figs. 7, 10, 11),
mGluRIs (see Fig. 4K ), GLAST, and GLT-1 (data not shown). The cytoplasmic protein extracts were used to measure protein levels of the
Dopamine- And cAMP-Regulated Phospho Protein 32 kDa (DARPP-32)
and of its phosphorylated version ( pDARPP-32; see Figs. 7, 10, 11). The
protein concentration was determined using spectrophotometer measures. We loaded equal amounts of proteins from WT and EAAC1 ⫺/⫺
mice in acrylamide gels (50 –100 g of proteins in 10 –12% acrylamide
gels). The proteins were blotted onto PVDF membranes (catalog #P2563;
Millipore Sigma) using a semidry blotting approach. The membranes
were then blocked with 5% nonfat milk in TBST, pH 7.6, and probed
using a primary antibody solution in which milk was replaced by BSA
(5% BSA in TBST; pH 7.6). We used the following primary antibodies:
rabbit anti D1R and D2R (1:200, RRID:AB_2039826 and RRID:
AB_2039828 respectively; Alomone Labs); rabbit anti mGluR5/1a (1:
500, RRID:AB_2492152; PhosphoSolutions); rabbit anti GLAST (1:1000,
RRID:AB_10695722; Cell Signaling Technology); rabbit anti GLT-1 (1:
1000, RRID:AB_2190743; Cell Signaling Technology); rabbit anti
DARPP-32 (1:1000, RRID:AB_823479; Cell Signaling Technology); rabbit antibodies against different pDARPP-32 isoforms ( pDARPP-32 T34,
1:500, catalog #12438; Cell Signaling Technology), ( pDARPP-32 T75 and
pDARPP-32 S97, 1:1000, RRID:AB_2169010 and RRID:AB_11217633,
respectively; Cell Signaling Technology), ( pDARPP-32 S130, 1:500,
RRID:AB_2492070; PhosphoSolutions), mCherry (RRID:AB_2614470;
RocklandAntibodiesandAssays),and ␤-actin(1:1000,RRID:AB_2223172;Cell
Signaling Technology). The membranes were incubated with the primary antibodies overnight. The pDARPP-32 S130 antibody was incubated
at RT; all other antibodies were incubated at 4°C. The secondary antibody incubation (biotinylated horse anti-rabbit IgG, RRID:AB_2336201;
Vector Laboratories) was performed for 1–2 h at RT with 5% nonfat milk
in TBST, pH 7.6. The following secondary antibody dilutions were used
for different proteins: 1:200 pDARPP-32 T34; 1:500 mCherry; 1:1000 for
D2R, GLAST, GLT-1, and pDARPP-32 S130; 1:2000 mGluRI; 1:3000
pDARPP-32 T75; 1:4000 D1R; and 1:5000 pDARPP-32 S97 and ␤-actin).
Preadsorption experiments were performed using the control antigen
provided by the supplier of the primary antibodies (Alomone Labs) according to the manufacturer’s instructions (1 g/g antibody). We amplified the immunolabeling reactions with the Vectastain ABC kit (1:
1000 for pDARPP-32 T34 and 1:2000 for all other proteins, RRID:
AB_2336819; Vector Laboratories) and the Clarity Western ECL (catalog
#170 –5060; Bio-Rad) as a substrate for the peroxidase enzyme. For semiquantitative analysis, protein band images were collected as 16-bit images using a digital chemiluminescence imaging system (ChemiDoc,
Bio-Rad or c300, Azure Biosystems) at different exposures (0.5–200 s).
Each image was converted to an 8-bit image for image analysis, which was
performed using Fiji software. Only images collected at exposure times
that did not lead to pixel saturation were included in the analysis. The
intensity of each band was calculated as the mean gray value in an ROI
surrounding each band of interest in three images collected using different exposure times. All band intensity values were normalized for the
band intensity of ␤-actin in the same sample.
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Table 7. Reaction parameters used in the models
Reaction

kon (M ⫺1 s ⫺1)

k-off (s ⫺1)

DARPP-32 ⫹ CdK5 ¡ DARPP-32 - CdK5
DARPP-32 - CdK5 ¡ DARPP-32 T75 ⫹ CdK5
DARPP-32 ⫹ CK1 ¡ DARPP-32 - CK1
DARPP-32 - CK1 ¡ DARPP-32 S130 ⫹ CK1
DARPP-32 ⫹ PKA ¡ DARPP-32 - PKA
DARPP-32 - PKA ¡ DARPP-32 T34 ⫹ PKA
DARPP-32 T34 ⫹ CdK5 ¡ DARPP-32 T34 - CdK5
DARPP-32 T34 - CdK5 ¡ DARPP-32 T34,T75 ⫹ CdK5
DARPP-32 T34 ⫹ CK1 ¡ DARPP-32 T34 - CK1
DARPP-32 T34 - CK1 ¡ DARPP-32 T34,S130 ⫹ CK1
DARPP-32 T34 ⫹ PP2B ¡ DARPP-32 T34 - PP2B
DARPP-32 T34 - PP2B ¡ DARPP-32 ⫹ PP2B
DARPP-32 T75 ⫹ CK1 ¡ DARPP-32 T75 - CK1
DARPP-32 T75 - CK1 ¡ DARPP-32 T75,S130 ⫹ CK1
DARPP-32 T75 ⫹ PKA ¡ DARPP-32 T75 - PKA
DARPP-32 T75 - PKA ¡ DARPP-32 T34,T75 ⫹ PKA
DARPP-32 T75 ⫹ PP2A ¡ DARPP-32 T75 - PP2A
DARPP-32 T75 - PP2A ¡ DARPP-32 ⫹ PP2A
DARPP-32 T75 ⫹ PP2AP ¡ DARPP-32 T75 - PP2AP
DARPP-32 T75 - PP2AP ¡ DARPP-32 T75 ⫹ PP2AP
DARPP-32 S130 ⫹ CdK5 ¡ DARPP-32 S130 - CdK5
DARPP-32 S130 - CdK5 ¡ DARPP-32 T75,S130 ⫹ CdK5
DARPP-32 S130 ⫹ PKA ¡ DARPP-32 S130 - PKA
DARPP-32 S130 - PKA ¡ DARPP-32 T34,S130 ⫹ PKA
DARPP-32 S130 ⫹ PP2C ¡ DARPP-32 S130 - PP2C
DARPP-32 S130 - PP2C ¡ DARPP-32 ⫹ PP2C
DARPP-32 T34,T75 ⫹ CK1 ¡ DARPP-32 T34,T75 - CK1
DARPP-32 T34,T75 - CK1 ¡ DARPP-32 T34,T75,S130 ⫹ CK1
DARPP-32 T34,T75 ⫹ PP2A ¡ DARPP-32 T34,T75 - PP2A
DARPP-32 T34,T75 - PP2A ¡ DARPP-32 T34 ⫹ PP2A
DARPP-32 T34,T75 ⫹ PP2AP ¡ DARPP-32 T34,T75 - PP2AP
DARPP-32 T34,T75 - PP2AP ¡ DARPP-32 T34 ⫹ PP2AP
DARPP-32 T34,T75 ⫹ PP2B ¡ DARPP-32 T34,T75 - PP2B
DARPP-32 T34,T75 - PP2B ¡ DARPP-32 T75 ⫹ PP2B
DARPP-32 T34,S130 ⫹ CdK5 ¡ DARPP-32 T34,S130 - CdK5
DARPP-32 T34,S130 - CdK5 ¡ DARPP-32 T34,T75,S130 ⫹ CdK5
DARPP-32 T34,S130 ⫹ PP2B ¡ DARPP-32 T34,S130 - PP2B
DARPP-32 T34,S130 - PP2B ¡ DARPP-32 S130 ⫹ PP2B
DARPP-32 T34,S130 ⫹ PP2C ¡ DARPP-32 T34,S130 - PP2C
DARPP-32 T34,S130 - PP2C ¡ DARPP-32 T34 ⫹ PP2C
DARPP-32 T75,S130 ⫹ PKA ¡ DARPP-32 T75,S130 - PKA
DARPP-32 T75,S130 - PKA ¡ DARPP-32 T34,T75,S130 ⫹ PKA
DARPP-32 T75,S130 ⫹ PP2A ¡ DARPP-32 T75,S130 - PP2A
DARPP-32 T75,S130 - PP2A ¡ DARPP-32 S130 ⫹ PP2A
DARPP-32 T75,S130 ⫹ PP2AP ¡ DARPP-32 T75,S130 - PP2AP
DARPP-32 T75,S130 - PP2AP ¡ DARPP-32 S130 ⫹ PP2AP
DARPP-32 T75,S130 ⫹ PP2C ¡ DARPP-32 T75,S130 - PP2C
DARPP-32 T75,S130 - PP2C ¡ DARPP-32 T75 ⫹ PP2C
DARPP-32 T34,T75,S130 ⫹ PP2A ¡ DARPP-32 T34,T75,S130 - PP2A
DARPP-32 T34,T75,S130 - PP2A ¡ DARPP-32 T34,S130 ⫹ PP2A
DARPP-32 T34,T75,S130 ⫹ PP2AP ¡ DARPP-32 T34,T75,S130 - PP2AP
DARPP-32 T34,T75,S130 - PP2AP ¡ DARPP-32 T34,S130 ⫹ PP2AP
DARPP-32 T34,T75,S130 ⫹ PP2B ¡ DARPP-32 T34,T75,S130 - PP2B
DARPP-32 T34,T75,S130 - PP2B ¡ DARPP-32 T75,S130 ⫹ PP2B
DARPP-32 T34,T75 ⫹ PP2C ¡ DARPP-32 T34,T75,S130 - PP2C
DARPP-32 T34,T75,S130 - PP2C ¡ DARPP-32 T34,T75,S130 ⫹ PP2C
CK1P ⫹ PP2B ¡ CK1P - PP2B
CK1P - PP2B ¡ CK1 ⫹ PP2B
CK1 ¡ CK1P
PDE ⫹ PKA ¡ PDE - PKA
PDE - PKA ¡ PDEP ⫹ PKA
PDEP ¡ PDE
PP2A ⫹ PKA ¡ PP2A - PKA
PP2A - PKA ¡ PP2AP ⫹ PKA
PP2AP ¡ PP2A

5.6e ⫹ 06

12
3
12
3
10.8
2.7
12
3
12
3
16
4
12
3
10.8
0
24
10
24
40
12
3
10.8
2.7
12
3
12
3
24
10
40
24
1,600
4
12
3
0.12
0.03
12
3
10.8
0
24
10
40
24
12
3
24
10
40
24
120
0.03
3
12
24
6

4.4e ⫹ 06
5.6e ⫹ 06
5.6e ⫹ 06
4.4e ⫹ 06
1e ⫹ 08
4.4e ⫹ 06
5.6e ⫹ 06
3.8e ⫹ 06
1.7e ⫹ 07
5.6e ⫹ 06
5.6e ⫹ 06
7.5e ⫹ 06
4.4e ⫹ 06
3.8e ⫹ 06
1.7e ⫹ 07
1e ⫹ 08
5.6e ⫹ 06
7.5e ⫹ 04
7.5e ⫹ 06
5.6e ⫹ 06
3.8e ⫹ 06
1.7e ⫹ 07
7.5e ⫹ 06
3.8e ⫹ 06
1.7e ⫹ 07
7.5e ⫹ 04
7.5e ⫹ 06
3e ⫹ 08

␣ (s ⫺1)

1
6e ⫹ 06

36
9

1e ⫹ 08

16
4

0.1

5
(Table continues)
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Table 7. Continued
Reaction

kon (M ⫺1 s ⫺1)

PP2B (inactive) ⫹ Ca 2⫹ ¡ PP2B (inactive) - Ca 2⫹
PP2B (inactive) - Ca 2⫹ ⫹ Ca 2⫹ ¡ PP2B
R2C2 ⫹ cAMP ¡ cAMP - R2C2
cAMP - R2C2 ⫹ cAMP ¡ cAMP2 - R2C2
cAMP2 - R2C2 ⫹ cAMP ¡ cAMP3 - R2C2
cAMP3 - R2C2 ⫹ cAMP ¡ cAMP4 - R2C2
cAMP4-R2C ⫹ PKA ¡ cAMP4 - R2C2
cAMP4-R2 ⫹ PKA ¡ cAMP4 - R2C
cAMP ⫹ PDE ¡ cAMP - PDE
cAMP-PDE ¡ AMP ⫹ PDE
cAMP ⫹ PDEP ¡ cAMP -PDEP
cAMP-PDEP ¡ AMP ⫹ PDEP
Ca 2⫹ ¡ NULL
Ca 2⫹ ⫹ CK2 ¡ CK2-Ca 2⫹
CK2-Ca 2⫹ ⫹ DARPP-32 ¡ DARPP-32 - CK2 - Ca 2⫹
DARPP-32-CK2-Ca 2⫹ ¡ DARPP-32 S97 ⫹ CK2 - Ca 2⫹
DARPP-32 S97 ⫹ PP2A ¡ DARPP-32 S97 - PP2A
DARPP-32 S97 - PP2A ¡ DARPP-32 ⫹ PP2A
DARPP-32 T34,S97 ⫹ PP2A ¡ DARPP-32 T34,S97 - PP2A
DARPP-32 T34,S97 - PP2A ¡ DARPP-32 T34 ⫹ PP2A
DARPP-32 T34,S97 - PP2A ¡ DARPP-32 S97 ⫹ PP2A
DARPP-32 T75,S97 ⫹ PP2A ¡ DARPP-32 T75,S97 - PP2A
DARPP-32 T75,S97 - PP2A ¡ DARPP-32 T75 ⫹ PP2A
DARPP-32 T75,S97 - PP2A ¡ DARPP-32 S97 ⫹ PP2A
DARPP-32 S97,S130 ⫹ PP2A ¡ DARPP-32 S97,S130 - PP2A
DARPP-32 S97,S130 - PP2A ¡ DARPP-32 S130 ⫹ PP2A
DARPP-32 S97,S130 - PP2A ¡ DARPP-32 S97 ⫹ PP2A
DARPP-32 T34,T75,S97 ⫹ PP2A ¡ DARPP-32 T34,T75,S97 - PP2A
DARPP-32 T34,T75,S97 - PP2A ¡ DARPP-32 T75,S97 ⫹ PP2A
DARPP-32 T34,T75,S97 - PP2A ¡ DARPP-32 T34,S97 ⫹ PP2A
DARPP-32 T34,T75,S97 - PP2A ¡ DARPP-32 T34,T75 ⫹ PP2A
DARPP-32 T75,S97,S130 ⫹ PP2A ¡ DARPP-32 T75,S97,S130 - PP2A
DARPP-32 T75,S97,S130 - PP2A ¡ DARPP-32 S97,S130 ⫹ PP2A
DARPP-32 T75,S97,S130 - PP2A ¡ DARPP-32 T75,S130 ⫹ PP2A
DARPP-32 T75,S97,S130 - PP2A ¡ DARPP-32 T75,S97 ⫹ PP2A
DARPP-32 T34,S97,S130 ⫹ PP2A ¡ DARPP-32 T34,S97,S130 - PP2A
DARPP-32 T34,S97,S130 - PP2A ¡ DARPP-32 S97,S130 ⫹ PP2A
DARPP-32 T34,S97,S130 - PP2A ¡ DARPP-32 T34,S130 ⫹ PP2A
DARPP-32 T34,S97,S130 - PP2A ¡ DARPP-32 T34,S97 ⫹ PP2A
DARPP-32 T34,T75,S130 ⫹ PP2A ¡ DARPP-32 T34,T75,S130 - PP2A
DARPP-32 T34,T75,S130 - PP2A ¡ DARPP-32 T75,S130 ⫹ PP2A
DARPP-32 T34,T75,S130 - PP2A ¡ DARPP-32 T34,S130 ⫹ PP2A
DARPP-32 T34,T75,S130 - PP2A ¡ DARPP-32 T34,T75 ⫹ PP2A
DARPP-32 T34,T75,S97,S130 ⫹ PP2A ¡ DARPP-32 T34,T75,S97,S130 - PP2A
DARPP-32 T34,T75,S97,S130 - PP2A ¡ DARPP-32 T75,S97,S130 ⫹ PP2A
DARPP-32 T34,T75,S97,S130 - PP2A ¡ DARPP-32 T34,S97,S130 ⫹ PP2A
DARPP-32 T34,T75,S97,S130 - PP2A ¡ DARPP-32 T34,T75,S130 ⫹ PP2A
DARPP-32 T34,T75,S97,S130 - PP2A ¡ DARPP-32 T34,T75 ⫹ PP2A
DARPP-32 S97 ⫹ CdK5 ¡ DARPP-32 S97 - CdK5
DARPP-32 S97 - CdK5 ¡ DARPP-32 T75,S97 ⫹ CdK5
DARPP-32 T34,S97 ⫹ CdK5 ¡ DARPP-32 T34,S97 - CdK5
DARPP-32 T34,S97 - CdK5 ¡ DARPP-32 T34,T75,S97 ⫹ CdK5
DARPP-32 S97,S130 ⫹ CdK5 ¡ DARPP-32 S97,S130 - CdK5
DARPP-32 S97,S130 - CdK5 ¡ DARPP-32 T75,S97,S130 ⫹ CdK5
DARPP-32 T34,S97,S130 ⫹ CdK5 ¡ DARPP-32 T34,S97,S130 - CdK5
DARPP-32 T34,S97,S130 - CdK5 ¡ DARPP-32 T34,T75,S97,S130 ⫹ CdK5
DARPP-32 S97 ⫹ CK1 ¡ DARPP-32 S97 - CK1
DARPP-32 S97 - CK1 ¡ DARPP-32 S97,S130 ⫹ CK1
DARPP-32 T34,S97 ⫹ CK1 ¡ DARPP-32 T34,S97 - CK1
DARPP-32 T34,S97 - CK1 ¡ DARPP-32 T34,S97,S130 ⫹ CK1
DARPP-32 T75,S97 ⫹ CK1 ¡ DARPP-32 T75,S97 - CK1
DARPP-32 T75,S97 - CK1 ¡ DARPP-32 T75,S97,S130 ⫹ CK1
DARPP-32 T34,T75,S97 ⫹ CK1 ¡ DARPP-32 T34,T75,S97 - CK1
DARPP-32 T34,T75,S97 - CK1 ¡ DARPP-32 T34,T75,S97,S130 ⫹ CK1
DARPP-32 T34,S97 ⫹ PP2B ¡ DARPP-32 T34,S97 - PP2B

1e ⫹ 15
3e ⫹ 15
5.4e ⫹ 07
5.4e ⫹ 07
7.5e ⫹ 07
7.5e ⫹ 07
1.8e ⫹ 07
1.8e ⫹ 07
2.52e ⫹ 06
5.04e ⫹ 06

k-off (s ⫺1)

␣ (s ⫺1)

1
1
33
33
110
32.5
60
60
40
10
80
20
0.6

1e ⫹ 15
4.4e5
3.8e ⫹ 06
3.8e ⫹ 06
3.8e ⫹ 06
3.8e ⫹ 06
3.8e ⫹ 06

3.8e ⫹ 06

3.8e ⫹ 06

3.8e ⫹ 06

3.8e ⫹ 06

5.6e ⫹ 06
5.6e ⫹ 06
5.6e ⫹ 06
5.6e ⫹ 06
4.4e ⫹ 06
4.4e ⫹ 06
4.4e ⫹ 06
4.4e ⫹ 06
7.5e ⫹ 04

3e ⫹ 15
12
3
24
10
24
10
10
24
10
10
24
10
10
24
10
10
10
24
10
10
10
24
10
10
10
24
10
10
10
24
10
10
10
10
12
3
12
3
12
3
12
3
12
3
12
3
12
3
12
3
120
(Table continues)
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Table 7. Continued
Reaction
DARPP-32 T34,S97 - PP2B ¡ DARPP-32 S97 ⫹ PP2B
DARPP-32 T34,T75,S97 ⫹ PP2B ¡ DARPP-32 T34,T75,S97 - PP2B
DARPP-32 T34,T75,S97 - PP2B ¡ DARPP-32 T75,S97 ⫹ PP2B
DARPP-32 T34,S97,S130 ⫹ PP2B ¡ DARPP-32 T34,S97,S130 - PP2B
DARPP-32 T34,S97,S130 - PP2B ¡ DARPP-32 S97,S130 ⫹ PP2B
DARPP-32 T34,T75,S130 ⫹ PP2B ¡ DARPP-32 T34,T75,S130 - PP2B
DARPP-32 T34,T75,S130 - PP2B ¡ DARPP-32 T75,S130 ⫹ PP2B
DARPP-32 T34,T75,S97,S130 ⫹ PP2B ¡ DARPP-32 T34,T75,S97,S130 - PP2B
DARPP-32 T34,T75,S97,S130 - PP2B ¡ DARPP-32 T75,S97,S130 ⫹ PP2B
DARPP-32 S97,S130 ⫹ PP2C ¡ DARPP-32 S97,S130 - PP2C
DARPP-32 S97,S130 - PP2C ¡ DARPP-32 S97 ⫹ PP2C
DARPP-32 T34,S97,S130 ⫹ PP2C ¡ DARPP-32 T34,S97,S130 - PP2C
DARPP-32 T34,S97,S130 - PP2C ¡ DARPP-32 T34,S97 ⫹ PP2C
DARPP-32 T75,S97,S130 ⫹ PP2C ¡ DARPP-32 T75,S97,S130 - PP2C
DARPP-32 T75,S97,S130 - PP2C ¡ DARPP-32 T75,S97 ⫹ PP2C
DARPP-32 T34,T75,S97,S130 ⫹ PP2C ¡ DARPP-32 T34,T75,S97,S130 - PP2C
DARPP-32 T34,T75,S97,S130 - PP2C ¡ DARPP-32 T34,T75,S97 ⫹ PP2C

Acute slice preparation, electrophysiology experiments, and
data analysis
Acute coronal slices of the mouse striatum were obtained from WT and
EAAC1 ⫺/⫺ mice of either sex (P16 –P24) that were deeply anesthetized
with isoflurane and decapitated in accordance with SUNY–Albany Animal Care and Use Committee guidelines. The brain was rapidly removed
and placed in ice-cold slicing solution bubbled with 95% O2/5% CO2
containing the following (in mM): 119 NaCl, 2.5 KCl, 0.5 CaCl2, 1.3
MgSO4䡠H2O, 4 MgCl2, 26.2 NaHCO3, 1 NaH2PO4, and 22 glucose, 320
mOsm, pH 7.4. The slices (250 m thick) were prepared using a vibrating
blade microtome (VT1200S; Leica Microsystems). Once prepared, the
slices were stored in this solution in a submersion chamber at 36°C for 30
min and at RT for at least 30 min and up to 5 h. Unless otherwise stated,
the recording solution contained the following (in mM): 119 NaCl, 2.5
KCl, 1.2 CaCl2, 1 MgCl2, 26.2 NaHCO3, and 1 NaH2PO4, 22 glucose, 300
mOsm, pH 7.4. This solution was also used to fill the glass capillaries used
for extracellular field recordings. We identified the DLS under brightfield illumination using an upright fixed-stage microscope (BX51 WI;
Olympus). Stimulating and recording electrodes were both placed in the
DLS ⬃100 m away from each other. Postsynaptic responses were
evoked by delivering constant voltage electrical pulses (50 s) through a
stimulating bipolar stainless steel electrode [catalog #MX21AES(JD3);
Frederick Haer]. The resistance of the recording electrode was ⬃1.5 M⍀
and was monitored throughout the experiments. Data were discarded if
the resistance changed ⬎20% during the course of the experiment. Picrotoxin (100 M) was added to the recording solution to block GABAA
receptors. All recordings were obtained using a Multiclamp 700B amplifier and filtered at 10 kHz (Molecular Devices), converted with an 18-bit
200 kHz A/D board (HEKA), digitized at 10 kHz, and analyzed offline
with custom-made software (A.S.) written in IgorPro 6.36 (Wavemetrics). Tetrodotoxin (TTX) was purchased from Alomone Labs (catalog
#T-550). NBQX, APV, (S)-(⫹)-␣-Amino-4-carboxy-2-methylbenzeneaceticacid (LY367385), and 2-Methyl-6-( phenylethynyl)pyridine hydrochloride (MPEP) were purchased from Tocris Bioscience (catalog #1044,
0105/10, 1237/10, and 1212/10) and Hello Bio (catalog #HB0443,
HB0251, HB0398, HB0426). All other chemicals were purchased from
Millipore Sigma. All recordings were performed at RT.

Stereotaxic intracranial injections

Male and female D1 Cre/⫹ and WT mice (P14 –P16) were anesthetized
with isoflurane (induction: 5% in 100% O2 at 1–2 l/min; maintenance:
3% in 100% O2 at 1–2 l/min) and placed in the stereotaxic frame of a
motorized drill and injection robot (Neurostar). After making a skin
incision and thinning the skull under aseptic conditions, we injected 100
nl of the AAV construct AAV-hSyn-DIO-hM3D(Gq)-mCherry (University of North Carolina, Chapel Hill, NC) unilaterally in either the left or
right DLS using a Hamilton syringe at a rate of 100 nl/min. The noninjected striatum was used as an internal control. The injection coordinates

kon (M ⫺1 s ⫺1)

k-off (s ⫺1)

␣ (s ⫺1)

0.03
120
0.03
120
0.03
120
0.03
120
0.03
12
3
12
3
12
3
12
3

7.5e ⫹ 04
7.5e ⫹ 04
7.5e ⫹ 04
7.5e ⫹ 04
7.5e ⫹ 06
7.5e ⫹ 06
7.5e ⫹ 06
7.5e ⫹ 06

from lambda were AP: ⫺2.5 mm, ML: ⫾2.0 mm, DV: ⫹5.0 mm. After
the stereotaxic injections, the mice were returned to their home cage for
7 d and then received daily intraperitoneal injections of NaCl 0.9%
(10 l/g, v/w) for 7 d. Two weeks after the stereotaxic surgery, mice
received a single intraperitoneal injection of CNO (5 mg/kg in NaCl
0.9%; catalog #BML-NS105-0005; Enzo Life Sciences). One hour after
the CNO injection, we acquired videos to monitor the grooming behavior of the mice. Two hours after the CNO injections, we euthanized the
mice to isolate the left and right striatum and cortex to be used for
Western blot analysis.

Computer modeling
Kinetic model of mGluRI. We used ChanneLab (Synaptosoft) to estimate
the mGluRI open probability using a kinetic scheme of mGluRI activation (Marcaggi et al., 2009). An analytic approach was used to determine
the relationship between glutamate transporter concentration and ambient glutamate concentration (see Fig. 4L). Briefly, under steady-state
conditions, the relationship between glutamate transporter and extracellular glutamate concentration can be described by a modified version of
the Michaelis–Menten equation (Sun et al., 2014), as follows:

关 Transporter 兴 ⫽ A 䡠

K M ⫹ 关 Glutamate 兴
Glutamate

In this equation, KM ⫽ 27 M (Sun et al., 2014). The proportionality
constant A can be calculated by setting [glutamate] ⫽ 25 nM (the experimentally measured ambient glutamate concentration in the striatum;
Chiu and Jahr, 2017) and [transporter] ⫽ 140 M (the estimated concentration of glutamate transporters in the brain; Lehre and Danbolt,
1998). The data shown in Figure 4L (blue) were normalized to obtain the
normalized transporter concentration ( y-axis) at different steady-state
ambient glutamate concentrations (x-axis). The analysis of this relationship was performed using custom software written in IgorPro (Wavemetrics; A.S.).
3D Monte Carlo model of pDARPP-32 phosphorylation. We used
Blender (2.75) to create a simplified 3D mesh geometry, which we used as
an in silico representation of an excitatory postsynaptic terminal (i.e.,
spine head). This 3D geometry was shaped as a 1 m 3 volume sphere of
radius r ⫽ 0.62 m with reflective properties for any diffusing molecule
(i.e., a diffusing molecule contacting the sphere bounces back without
disappearing from the simulation environment). This geometry was exported into Model Description Language and was used in the MCell (3.4)
3D Monte Carlo simulation environment. At the beginning of each simulation, we released DARPP-32 and other protein kinases and phosphatases in the sphere, at the concentrations specified in Table 6. We let the
system equilibrate for 150 s to allow all molecules to diffuse evenly and
equilibrate throughout the entire simulation environment (i.e., the
sphere). After this equilibration time, we released Ca 2⫹ (1 M–1 mM)
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from the center of the sphere using single pulses or trains of 10 pulses
(0.1–10 Hz) as described in Figure 8. The diffusion coefficient of Ca 2⫹
was set to D* ⫽ 2.2e-6 cm 2/s (Allbritton et al., 1992). The diffusion
coefficient of all other molecules was set to D* ⫽ 5e-8 cm 2/s (Li et al.,
2015). The initial conditions (Table 6) and reactions (Table 7) were
modeled according to the kinetic schemes reported by Fernandez et al.
(2006) to which we added new reactions for pDARPP-32 S97. Briefly,
DARPP-32 is phosphorylated in position T34 by the cAMP-dependent
protein kinase A (PKA; pDARPP-32 T34), in position T75 by the cyclindependent kinase 5 (CdK5; pDARPP-32 T75), in position S97 by casein
kinase 2 (CK2; pDARPP-32 S97), and in position S130 by casein kinase 1
(CK1; pDARPP-32 S130). The phosphorylation of each position was independent of the phosphorylation state of other positions, as specified by
the available kinetic parameters. Each simulation was run 100 times.
Each run lasted 500 s and consisted of 5000 iterations with a time step
⌬t ⫽ 0.1 s. The concentration of each molecule in the sphere was monitored at every ⌬t. We used custom-made scripts written in Python 3.5
(A.S.) to execute each run and averaged the results obtained over multiple runs, which are shown in Figure 8. In this figure, pDARPP-32 S130
represents the sum of all pDARPP-32 states that have one phosphate
group attached to position S130 regardless of the phosphorylation state
of other sites.

Experimental design and statistical analysis

Data are presented as mean ⫾ SEM unless otherwise stated. All experiments were performed on multiple mice of either sex. Statistical significance was determined by Student’s paired or unpaired t test, as
appropriate (IgorPro 6.36). Differences were considered significant at
p ⬍ 0.05 (*p ⬍ 0.05; **p ⬍ 0.01; ***p ⬍ 0.001).

Results

Behavioral phenotype of EAAC1 ⴚ/ⴚ mice
As a first step in our analysis, we performed a comprehensive behavioral assay of constitutive EAAC1 knock-out mice (EAAC1 ⫺/⫺).
These mice, originally developed by (Peghini et al., 1997), were
obtained by inserting a pgk neomycin resistance cassette in the
Slc1a1 gene, which encodes the neuronal glutamate transporter
EAAC1. We assessed their general phenotype and tested for the
presence of traits that might be indicative of compulsive behaviors. In the SHIRPA screen, we assessed the presence of disturbances in gait, posture, muscle tone deficits, and abnormalities in
motor control and coordination (Fig. 1). We performed this
analysis on mice aged P14 –P35 to cover a wide range of ages,
starting when EAAC1 reaches its peak expression in the striatum
at P14 (Furuta et al., 1997) and ending 2 weeks after glutamatergic corticostriatal synapses and dopamine receptors and terminals complete their maturation at P21 (Hattori and McGeer,
1973; Stamford, 1989; Teicher et al., 1995; Sharpe and Tepper,
1998). The results of the SHIRPA screen evidenced subtle motor
deficits that had not been reported when the mice were first generated and characterized (Peghini et al., 1997). These subtle abnormalities were present throughout the entire P14 –P35 age
range and could be detected when pooling data from EAAC1 ⫺/⫺
mice of either sex (Fig. 1) and when analyzing male and female
mice separately (Fig. 1-1, available at https://doi.org/10.1523/
JNEUROSCI.1906-17.2017.f1-1).
The overall level of motor activity, measured as distance traveled and time spent on a running wheel, was similar in WT and
EAAC1 ⫺/⫺ mice ( p ⫽ 0.35 and p ⫽ 0.12, respectively; Fig. 2A).
Consistent with these findings, the total distance traveled by WT
and EAAC1 ⫺/⫺ mice in an open-field test was also similar ( p ⫽
0.28; Fig. 2B, middle). What we noticed while performing this
test, however, was that the EAAC1 ⫺/⫺ mice were less immobile
(**p ⫽ 4.6e-3) because they fidgeted when they resided in a given
spot of the open-field arena (Fig. 2B, right). This restless behavior
can be indicative of increased anxiety-like and motor behaviors in

Figure 1. A battery of SHIRPA tests reveals subtle abnormalities in male and female EAAC1 ⫺/⫺
mice. Parameter scores for a battery of SHIRPA primary screen test in male and female WT (white
bars) and EAAC1 ⫺/⫺ mice (red bars) aged P14 –P35. See Figure 1-1 for separate analysis of
male and female mice (available at https://doi.org/10.1523/JNEUROSCI.1906-17.2017.f1-1).

Bellini et al. • Neuronal Transporters Control Compulsive Behaviors

J. Neurosci., January 24, 2018 • 38(4):937–961 • 945

Figure 2. EAAC1 ⫺/⫺ mice show similar levels of motor activity but increased anxiety-like behaviors compared with WT mice. A, Summary of spontaneous locomotor activity in a free-spinning
flying saucer (left) in WT mice (n ⫽ 137) and EAAC1 ⫺/⫺ mice (n ⫽ 150) aged P14 –P35. No significant difference was detected in the mean distance (middle) and running time (right) between
WT and EAAC1 ⫺/⫺ mice ( p ⫽ 0.35 and p ⫽ 0.12, respectively). B, In the open-field test (left), WT mice (n ⫽ 153) and EAAC1 ⫺/⫺ mice (n ⫽ 149) traveled the same distance ( p ⫽ 0.28; middle),
but EAAC1 ⫺/⫺ mice showed a significant decrease in the proportion of immobile time (**p ⫽ 4.6e-3; right). C, In the elevated plus maze (left), EAAC1 ⫺/⫺ mice (n ⫽ 90) showed a larger
proportion of entries in closed arms compared with WT mice (n ⫽ 118, **p ⫽ 0.006; left). The thick white lines represent the mean proportion of entries in each arm. D, EAAC1 ⫺/⫺ mice spent a
larger proportion of time in the closed arms than WT mice (*p ⫽ 0.019; right). E, In the marble-burying test (left), EAAC1 ⫺/⫺ mice (n ⫽ 15; right) dug a (Figure legend continues.)
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EAAC1 ⫺/⫺ mice. This hypothesis was supported by data collected using the elevated plus maze test. EAAC1 ⫺/⫺ mice showed
an increased proportion of entries in the closed arms (**p ⫽
0.006; Fig. 2C) and spent more time there than in the open arms
(*p ⫽ 0.019; Fig. 2D). These results suggest that EAAC1 ⫺/⫺ mice
show increased anxiety-like behaviors. Consistent with these
findings, EAAC1 ⫺/⫺ mice buried more marbles than agematched WT mice in the marble-burying test (***p ⫽ 3.9e-11;
Fig. 2E), another test used to detect anxiety-like behaviors in mice
(Angoa-Perez et al., 2013). The different behavior of WT and
EAAC1 ⫺/⫺ mice could be detected across the entire age range of
mice that we tested (**p ⫽ 5.5e-3; Fig. 2F ). Similar results to the
ones described in Figure 2 were also observed when analyzing
male and female mice separately (Fig. 2-1, available at https://doi.
org/10.1523/JNEUROSCI.1906-17.2017.f2-1). Together, the results described so far, which were collected using different and
complementary behavioral tests, indicate that EAAC1 ⫺/⫺ mice have
increased anxiety-like behaviors compared with WT mice. However,
none of these tests points to the presence of specific abnormalities in
behaviors controlled specifically by the striatum.
The striatum exerts a unique role in the control of rulegoverned sequential behaviors, including sequential patterned
strokes performed during grooming, which are reminiscent of
the ritual hand-washing behaviors of patients with OCD (Berridge and Whishaw, 1992; Kalueff et al., 2016). Interestingly, the
striatum is also one of the brain regions that shows hyperactivity
in patients with OCD and that has the highest expression levels of
EAAC1 (Danbolt, 2001; Holmseth et al., 2012). When monitoring mice using a video camera positioned below the behavioral
arena, we noticed that EAAC1 ⫺/⫺ mice groomed more frequently than WT mice [WT: 6.7 ⫾ 0.7e-3 Hz (n ⫽ 23),
EAAC1 ⫺/⫺: 11.3 ⫾ 0.8e-3 Hz (n ⫽ 42), ***p ⫽ 4.9e-5]. The
duration of each grooming episode was similar to that of WT
mice [WT: 55.2 ⫾ 6.7 s (n ⫽ 42), EAAC1 ⫺/⫺: 45.4 ⫾ 3.5 s (n ⫽
72), p ⫽ 0.200; Fig. 3A–D]. These results could not be attributed
to the use of behavioral arenas with transparent floors (see Materials and Methods) because similar results were obtained when
the mice were monitored using a camera positioned above standard mouse cages [grooming frequency WT: 7.6 ⫾ 0.5e-3 Hz
(n ⫽ 39), p ⫽ 0.34; EAAC1 ⫺/⫺: 9.5 ⫾ 0.6e-3 Hz (n ⫽ 89), p ⫽
0.07; WT vs EAAC1 ⫺/⫺ *p ⫽ 0.024; data not shown]. The increased grooming frequency in EAAC1 ⫺/⫺ mice did not lead to
consistent hair loss or skin lesions associated with other pathological conditions, including trichotillomania (Welch et al., 2007;
Feusner et al., 2009). When grooming, the paws of EAAC1 ⫺/⫺
mice performed shorter trajectories [WT: 153.3 ⫾ 14.3 mm (n ⫽
36), EAAC1 ⫺/⫺: 47.9 ⫾ 6.0 mm (n ⫽ 43), ***p ⫽ 1.6e-6; Fig.
3 E, F], suggesting that the execution of fine movements performed during grooming is disrupted in these mice.
Previous work in rats and mice indicates that each grooming
episode consists of distinct phases characterized by the execution
of specific types of patterned strokes (Kalueff et al., 2007). These
different strokes can be classified in six different phases through
which mice groom in an orderly sequence along the rostrocaudal
axis of their body, from paws to tail (Kalueff et al., 2007). Accord4
(Figure legend continued.) significantly larger proportion of marbles than WT mice (n ⫽ 36,
middle; ***p ⫽ 3.9e-11). F, Color coding representing the proportion of mice digging a given
proportion of marbles (y-axis). The white line describes the behavior of 50% of the mouse
population. There is an average increase in the proportion of EAAC1 ⫺/⫺ mice digging a larger
proportion of marbles (**p ⫽ 5.5e-3). See Figure 2-1 for separate analysis of female and male
mice (available at https://doi.org/10.1523/JNEUROSCI.1906-17.2017.f2-1).
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ing to this classification, Phase 0 includes the time intervals during which mice do not groom and Phases 1–5 describe phases
during which mice groom their front paws, face, toes, hind legs,
and tail/genitals, respectively (Kalueff et al., 2007). The grooming
episodes of EAAC1 ⫺/⫺ mice contained a larger number of phases
than in WT mice [WT: 9.6 ⫾ 0.6 (n ⫽ 87), EAAC1 ⫺/⫺: 14.7 ⫾ 1.0
(n ⫽ 86), ***p ⫽ 2.9e-5; Fig. 3G]. The order of progression from
one phase to the next one was disrupted in EAAC1 ⫺/⫺ mice due
to the presence of an increased proportion of incorrect transitions [WT: 0.49 ⫾ 0.02 (n ⫽ 83), EAAC1 ⫺/⫺: 0.54 ⫾ 0.01 (n ⫽
85), *p ⫽ 0.021; Fig. 3H]. EAAC1 ⫺/⫺ mice spent less time in
Phase 0 [WT: 3.4 ⫾ 0.3 s (n ⫽ 22), EAAC1 ⫺/⫺: 2.3 ⫾ 0.2 (n ⫽ 34),
*p ⫽ 0.013), Phase 2 (WT: 17.5 ⫾ 2.1 s (n ⫽ 73), EAAC1 ⫺/⫺:
7.6 ⫾ 0.7 s (n ⫽ 82), ***p ⫽ 2.7e-5), Phase 3 (WT: 7.9 ⫾ 0.6 s (n ⫽
64), EAAC1 ⫺/⫺: 5.6 ⫾ 0.7 s (n ⫽ 65), *p ⫽ 0.020), and Phase 5
(WT: 8.0 ⫾ 0.7 (n ⫽ 30), EAAC1 ⫺/⫺: 3.9 ⫾ 0.4 s (n ⫽ 29), ***p ⫽
4.8e-6; Fig. 3I]. WT mice spent most of their grooming time
rubbing their torso, whereas EAAC1 ⫺/⫺ mice mostly licked their
paws (Fig. 3J ). The increased grooming frequency and the disrupted syntactic structure of grooming episodes point to potential functional abnormalities in the striatum of EAAC1 ⫺/⫺ mice
and suggest that EAAC1 might contribute to altered execution of
stereotyped motor behaviors largely controlled by the striatum.
EAAC1 shapes synaptic transmission and plasticity in
the striatum
We tested directly the hypothesis that EAAC1 controls striatal
function ex vivo by obtaining extracellular field recordings in
acute brain slices containing the DLS, a domain of the striatum
specifically implicated with habit learning (Barnes et al., 2005;
Yin et al., 2005; Yin et al., 2006). We stimulated excitatory synaptic afferents by positioning a bipolar stimulating electrode in
the DLS 100 –200 m away from the recording electrode (Fig.
4A) and added the GABAA receptor blocker picrotoxin (100 M)
to the extracellular solution to isolate excitatory from inhibitory
responses. The extracellular recordings consist of a short-latency
fiber volley (FV) followed by a longer lasting population spike
(PS), as described by Misgeld et al. (1979). We first confirmed
that: (1) blocking action potential propagation with the voltagegated sodium channel blocker TTX (1 M) abolished both the FV
and PS (Fig. 4B); (2) the GluA antagonist NBQX (10 M) blocked
the PS but not the FV (Fig. 4C); and (3) TTX, applied in the
presence of NBQX, blocked the FV (Fig. 4C).
In the hippocampus, EAAC1 limits extrasynaptic GluN activation (Scimemi et al., 2009). To test for a similar role of EAAC1
in the DLS, we monitored the effect of the competitive, highaffinity GluN antagonist APV (50 M) on field recordings (Fig.
4 D, E). APV did not induce a significant change in the FV [Norm
FV amp WT: 1.03 ⫾ 0.08 (n ⫽ 12), EAAC1 ⫺/⫺: 1.10 ⫾ 0.05 (n ⫽
9), p ⫽ 0.41; Fig. 4 D, E] and PS/FV amplitude ratio [Norm PS/FV
amp WT: 0.99 ⫾ 0.09 (n ⫽ 12), EAAC1 ⫺/⫺: 1.02 ⫾ 0.08 (n ⫽ 9),
p ⫽ 0.82; Fig. 4 D, E], consistent with the limited involvement of
GluN receptors in mediating synaptic transmission at excitatory
synapses in the striatum (Sung et al., 2001). We performed additional control experiments to determine whether this result could
be due to compensatory upregulation of glial glutamate transporters in the absence of EAAC1, which could also limit GluN
activation. However, we did not find any significant difference in
the protein expression level of glial glutamate transporters
GLAST [Norm GLAST EAAC1 ⫺/⫺/WT: 1.02 ⫾ 0.09 (n ⫽ 10),
p ⫽ 0.81] and GLT-1 [Norm GLT-1 EAAC1 ⫺/⫺/WT: 1.07 ⫾ 0.23
(n ⫽ 8), p ⫽ 0.77] in protein extracts from the striatum of WT
and EAAC1 ⫺/⫺ mice (data not shown).
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The results of the electrophysiology experiments are important because they
suggest that the mechanisms by which
EAAC1 controls excitatory transmission
in the DLS may be different from the ones
described in the hippocampus (Scimemi
et al., 2009). Other types of glutamate receptors, such as the mGluRIs, are expressed
at high levels in extrasynaptic regions along
the plasma membrane of striatal neurons
(Paquet and Smith, 2003). These receptors are known to modulate cell excitability through a variety of mechanisms
including suppression of potassium channels (e.g., IAHP, IM, Ileak, and Islow) (Charpak et al., 1990; Womble and Moises,
1994; Ikeda et al., 1995; Lüthi et al., 1997)
and calcium channels (Crépel et al., 1994;
Kammermeier et al., 2000). Although
blocking mGluRI with type 1 and 5
mGluR antagonists did not affect the amplitude of the FV and PS in WT mice
[Norm FV amp WT: 1.08 ⫾ 0.05 (n ⫽ 13),
EAAC1 ⫺/⫺: 1.06 ⫾ 0.08 (n ⫽ 16), p ⫽
0.85; Fig. 4 F, G], it significantly increased
the PS/FV amplitude ratio in EAAC1 ⫺/⫺
mice [Norm FV amp WT: 0.91 ⫾ 0.09
(n ⫽ 13), EAAC1 ⫺/⫺: 1.21 ⫾ 0.06 (n ⫽
16), **p ⫽ 3.4e-3, WT vs EAAC1 ⫺/⫺ *p ⫽
0.012; Fig. 4 F, G]. We used separate control experiments to rule out that these results were due to time-dependent changes
in the FV and PS/FV amplitude over the
4

Figure 3. EAAC1 ⫺/⫺ mice show disrupted grooming behaviors. A, Relationship between the frequency and duration of
grooming episodes in WT mice. The inset represents a density plot of the data, with areas color coded in blue identifying the
duration and frequency of the most commonly observed grooming episodes. B, As in A but for EAAC1 ⫺/⫺ mice. C, Summary bar

graph of the frequency of grooming episodes [WT mice (n ⫽
23), EAAC1 ⫺/⫺ mice (n ⫽ 68), ***p ⫽ 4.9e-5]. D, Summary
bar graph of the mean duration of individual grooming episodes [WT mice (n ⫽ 42), EAAC1 ⫺/⫺ mice (n ⫽ 72), p ⫽
0.200]. E, Contour of the mouse body (white) and of the mouse
paws (magenta and green circles) detected by M-Track software and used to perform the analysis of paw trajectories
(Reeves et al., 2016). F, Summary bar graph of the mean trajectory length of mice paws as they move to execute a grooming episode [WT mice (n ⫽ 36), EAAC1 ⫺/⫺ mice (n ⫽ 43),
***p ⫽ 1.6e-6]. G, Summary bar graph of the mean number
of grooming phases represented in each grooming episode
[WT mice (n ⫽ 87), EAAC1 ⫺/⫺ mice (n ⫽ 86), ***p ⫽ 2.9e5]. H, Proportion of correct (left) and incorrect phase transitions in each grooming episode [WT mice (n ⫽ 83),
EAAC1 ⫺/⫺ mice (n ⫽ 85), *p ⫽ 0.021]. I, Summary of the
average duration of distinct phases represented in each
grooming episode. A decreased representation of Phases 0, 2,
3, and 5 is detected in EAAC1 ⫺/⫺ mice [Phase 0 WT mice (n ⫽
22), EAAC1 ⫺/⫺ mice (n ⫽ 34), *p ⫽ 0.013; Phase 1 WT mice
(n ⫽ 71), EAAC1 ⫺/⫺ mice (n ⫽ 79), p ⫽ 0.301; Phase 2 WT
mice (n ⫽ 73), EAAC1 ⫺/⫺ mice (n ⫽ 82), ***p ⫽ 2.7e-5;
Phase 3 WT mice (n ⫽ 64), EAAC1 ⫺/⫺ mice (n ⫽ 65), *p ⫽
0.020; Phase 4 WT mice (n ⫽ 39), EAAC1 ⫺/⫺ mice (n ⫽ 35),
p ⫽ 0.650; Phase 5 WT mice (n ⫽ 30), EAAC1 ⫺/⫺ mice (n ⫽
29), ***p ⫽ 4.8e-6]. J, Pie charts representing the normalized
distribution of different phases in each grooming episode. A
proportional increase in the representation of Phases 0 –3 is
detected in EAAC1 ⫺/⫺ mice. Significant p-values are included
in the figure color legend.
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Figure 4. Excitatory field recordings in the DLS of EAAC1 ⫺/⫺ mice show increased sensitivity to mGluRI blockers. A, Schematic illustration of the experimental design. The bipolar stimulating
electrode and the extracellular field recording electrode were positioned in the DLS. B, Left, Extracellular recordings of FV and PS in the DLS of WT mice in control conditions (black trace) and in the
presence of the voltage-gated sodium channel blocker TTX (1 M, orange trace). Right, Summary graph showing the effect of TTX on the FV amp [white bar (n ⫽ 5), ***p ⫽ 6.5e-4] and PS amplitude
[gray bar (n ⫽ 5), ***p ⫽ 6.6e-5]. C, Left, Extracellular recordings in the DLS of WT mice in control conditions (black trace), in the presence of the GluA antagonist NBQX (10 M, yellow trace), and
in the additional presence of TTX (1 M, orange trace). Right, Summary graph showing that NBQX reduces the PS amplitude [gray bars (n ⫽ 8), ***p ⫽ 4.6e-5] without affecting the FV amplitude
(white bars, p ⫽ 0.39). The FV and PS are blocked in the presence of both NBQX and TTX (***p ⫽ 2.9e-5 and ***p ⫽ 1.7e-7, respectively). D, Left, Extracellular recordings in the DLS of WT mice,
in control conditions (black trace), and in the presence of the GluN antagonist APV (50 M, green trace). Right, Extracellular recordings in the DLS of EAAC1 ⫺/⫺ mice, in control conditions (red trace),
and in the presence of APV (50 M, green trace). Each trace represents the average of 20 consecutive sweeps. E, Left, Summary graph showing the effect of APV on the FV in WT mice (n ⫽ 12) and
EAAC1 ⫺/⫺ mice (n ⫽ 9) (WT vs EAAC1 ⫺/⫺ p ⫽ 0.41). Right, Effect of APV on the PS/FV ratio recorded in WT mice (n ⫽ 12) and EAAC1 ⫺/⫺ mice (n ⫽ 9) (WT vs EAAC1 ⫺/⫺ p ⫽ 0.37). F, As in
D but for recordings obtained in control conditions and in the presence of the mGluRI blockers LY367385 (50 M) and MPEP (10 M; blue traces). G, Left, (Figure legend continues.)
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course of our experiments (Fig. 4 H, I ). To do this, we obtained
extracellular recordings without adding any drug to the external
solution apart from picrotoxin. There was no significant timedependent change in the FV amplitude [Norm FV amp WT:
0.99 ⫾ 0.06 (n ⫽ 8), p ⫽ 0.93; Norm FV amp EAAC1 ⫺/⫺: 1.12 ⫾
0.09 (n ⫽ 7), p ⫽ 0.24; WT vs EAAC1 ⫺/⫺ p ⫽ 0.28] and PS/FV
amplitude ratio in WT and EAAC1 ⫺/⫺ mice [Norm PS/FV amp
WT: 1.16 ⫾ 0.07 (n ⫽ 8), p ⫽ 0.058; Norm PS/FV amp
EAAC1 ⫺/⫺: 1.16 ⫾ 0.17 (n ⫽ 7), p ⫽ 0.38; WT vs EAAC1 ⫺/⫺ p ⫽
1.00; Fig. 4 H, I]. This suggests that the different sensitivity to
mGluRI antagonists of the PS/FV ratio in EAAC1 ⫺/⫺ mice is not
biased by potential time-dependent changes in our recordings. By
obtaining input/output curves, we confirmed that the effect of
mGluRI antagonists could be detected over a broad range of stimulus intensities in EAAC1 ⫺/⫺ mice (n ⫽ 16) but not in WT mice (n ⫽
13, **p ⫽ 2.1e-3; Fig. 4J).
The increased PS/FV sensitivity to mGluRI antagonists might
be explained by increased mGluRI expression or by increased
extracellular glutamate concentration in EAAC1 ⫺/⫺ mice. However, Western blot analysis showed that the mGluRI protein expression level is similar in WT and EAAC1 ⫺/⫺ mice [Norm band
intensity WT: 1 ⫾ 0.13 (n ⫽ 6), EAAC1 ⫺/⫺: 1.23 ⫾ 0.23 (n ⫽ 8),
p ⫽ 0.41; Fig. 4K]. To determine whether there might be an
increase in the extracellular glutamate concentration in the absence of EAAC1, we measured tonic GluN currents at hyperpolarized potentials to ensure glutamate transport via postsynaptic
EAAC1 (Wadiche et al., 1995; Zerangue and Kavanaugh, 1996).
Briefly, we voltage clamped MSNs at ⫺70 mV in the presence of
Mg 2⫹-free external solution containing blockers of GABAA (picrotoxin, 100 M) and GluA receptors (NBQX, 10 M) and measured the change in the holding current evoked by blocking GluN
receptors with APV (50 M). We did not detect any significant
change in the tonic GluN current [WT: 10.1 ⫾ 4.1 pA (n ⫽ 6),
EAAC1 ⫺/⫺: 15.8 ⫾ 9.3 pA (n ⫽ 6), p ⫽ 0.59] and tonic GluN
current density (tonic current/cell capacitance) in WT and
EAAC1 ⫺/⫺ mice [WT: 0.55 ⫾ 0.43 pA/pF (n ⫽ 6), EAAC1 ⫺/⫺:
0.36 ⫾ 0.19 pA/pF (n ⫽ 6), p ⫽ 0.70]. Is this result consistent with
our knowledge of mGluRI kinetics of activation and of glutamate
transporter control of ambient glutamate concentration? We addressed this question using a modeling approach. First, we estimated the mGluRI open probability over a broad range of
4
(Figure legend continued.) Summary graph showing the effect of LY367385 and MPEP on the FV
in WT mice (n ⫽ 13) and EAAC1 ⫺/⫺ mice (n ⫽ 16) (WT vs EAAC1 ⫺/⫺ p ⫽ 0.85). Right, Effect
of LY367385 and MPEP on the PS/FV ratio recorded in WT mice (n ⫽ 13) and EAAC1 ⫺/⫺ mice
(n ⫽ 16) (WT vs EAAC1 ⫺/⫺ *p ⫽ 0.012). H, As in D but for recordings obtained in timedependent control experiments. I, Left, Summary graph showing the effect on the FV in WT
mice (n ⫽ 8) and EAAC1 ⫺/⫺ mice (n ⫽ 7) (WT vs EAAC1 ⫺/⫺ p ⫽ 0.28). Right, Effect on the
PS/FV ratio recorded in WT mice (n ⫽ 8) and EAAC1 ⫺/⫺ mice (n ⫽ 7) (WT vs EAAC1 ⫺/⫺ p ⫽
1.00). J, Input/output relationship between the PS and FV amplitudes evoked by stimulating
excitatory afferents to the DLS. Left, mGluRI block does not alter the input/output curves in WT
mice (n ⫽ 13, p ⫽ 0.57). Right, mGluRI block increases the PS amp over a range of stimulus
intensities and FV amplitudes in EAAC1 ⫺/⫺ mice (n ⫽ 16, **p ⫽ 2.1e-3). K, Western blot
analysis showing similar levels of mGluRI expression in WT mice (n ⫽ 6) and EAAC1 ⫺/⫺ mice
(n ⫽ 8) ( p ⫽ 0.41). L, We used a kinetic model of mGluRI (Marcaggi et al., 2009) to determine
the open probability of these receptors at a range of extracellular glutamate concentrations
(pink). The striatum maintains the extracellular glutamate concentration at ⬃25 nM (Chiu and
Jahr, 2017) in the presence of ⬃140 M glutamate transporters (Lehre and Danbolt, 1998).
Reducing the concentration of glutamate transporters leads to increased extracellular glutamate concentrations (blue). EAAC1 accounts for ⬍5–10% of all glutamate transporters. According to our model (see Materials and Methods), loss of EAAC1 can cause a ⬍10 nM increase
in the ambient glutamate concentration (cyan). This change in the extracellular glutamate
concentration can only cause a marginal increase in the mGluRI open probability.
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extracellular glutamate concentrations using a kinetic model of
mGluRI (Marcaggi et al., 2009; Fig. 4L). Second, we calculated the
mGluRI open probability at the experimentally measured extracellular glutamate concentration in the striatum (⬃25 nM; Chiu
and Jahr, 2017) and the estimated concentration of glutamate
transporters (⬃140 M; Lehre and Danbolt, 1998). Third, we
used steady-state equations to determine the effect of a progressive reduction in the glutamate transporter concentration on the
extracellular glutamate concentration and the mGluRI open
probability. The results show that the mGluRI open probability is
very low (Po ⬃6e-4) when the glutamate transporter concentration is 140 M (i.s. Norm [Transporter ⫽ 1]) and the extracellular
glutamate concentration is 25 nM. Reducing the glutamate transporter concentration by 5%, consistent with the expected change
in glutamate transporter concentration in the absence of EAAC1
(Danbolt, 2001), would cause at most a 10 nM increase in the
ambient glutamate concentration (Fig. 4L). This increase in ambient glutamate concentration does not cause a significant
change in the mGluRI open probability. Therefore, the results of
the Western blot analysis and the modeling suggest that the increased contribution of mGluRI to the PS/FV ratio in EAAC1 ⫺/⫺
mice is not due to either increased mGluRI expression or increased
tonic mGluRI activation. Instead, it is consistent with increased
phasic activation of mGluRI in the absence of EAAC1.
The effect of EAAC1 on mGluRI activation is noteworthy because the activation of different types of glutamate receptors in
the DLS is crucial for the expression of long-term plasticity. Here,
long-term potentiation (LTP) relies on GluN and D1R activation
(Calabresi et al., 1992a; Partridge et al., 2000; Spencer and Murphy, 2000). Long-term depression (LTD) relies on mGluRI and
D2R activation and on postsynaptic calcium influx via L-type
calcium channels (Calabresi et al., 1992b; Gubellini et al., 2001;
Sung et al., 2001). In our experiments, high-frequency stimulation (HFS; 100 Hz ⫻ 1 s) of the DLS evoked LTD or LTP, depending on the extracellular calcium concentration ([Ca 2⫹]o; Fig.
5A). In WT mice, HFS induced LTP at a calcium concentration
that mimics the one found in the CSF {[Ca 2⫹]o ⫽ 1.2 mM; Norm
PS/FV amp WT: 1.21 ⫾ 0.09 (n ⫽ 7), *p ⫽ 0.047}. HFS did not
induce long-term plasticity at [Ca 2⫹]o ⫽ 2.5 mM [Norm PS/FV
amp WT: 1.09 ⫾ 0.07 (n ⫽ 7), p ⫽ 0.22]. Increasing the extracellular calcium concentration to [Ca 2⫹]o ⫽ 3.5 mM led to a robust
LTD, likely because of the increased driving force for postsynaptic calcium influx [Norm PS/FV amp WT: 0.84 ⫾ 0.06 (n ⫽ 11),
*p ⫽ 0.032; Fig. 5 A, C]. In EAAC1 ⫺/⫺ mice, HFS did not induce
any form of plasticity at any of the tested extracellular calcium concentrations {Norm PS/FV amp [Ca 2⫹]o ⫽ 1.2 mM EAAC1 ⫺/⫺:
1.04 ⫾ 0.06 (n ⫽ 8), p ⫽ 0.50; [Ca 2⫹]o ⫽ 2.5 mM EAAC1 ⫺/⫺: 0.96 ⫾
0.04 (n ⫽ 12), p ⫽ 0.28; [Ca 2⫹]o ⫽ 3.5 mM EAAC1 ⫺/⫺: 1.05 ⫾ 0.06
(n ⫽ 7), p ⫽ 0.46; Fig. 5B,D}. Loss of LTD in EAAC1 ⫺/⫺ mice is
consistent with altered mGluRI activation. However, loss of LTP
suggests that other receptors, in addition to mGluRI, might be
disrupted in the absence of EAAC1. Therefore, we performed
additional experiments to determine what molecular mechanism could account for the loss of LTP in the DLS of EAAC1 ⫺/⫺
mice.
EAAC1 promotes dopamine receptor expression
Loss of LTP in EAAC1 ⫺/⫺ mice is surprising because this form of
plasticity in the striatum does not require mGluRI, but rather
GluN and D1R activation. The electrophysiology experiments in
Figure 4 do not support a different contribution of GluN receptors to excitatory synaptic transmission in the DLS of EAAC1 ⫺/⫺
mice,and therefore point to an effect of EAAC1 on D1Rs. To test
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Figure 5. Ca 2⫹ dependence of long-term plasticity is lost in EAAC1 ⫺/⫺ mice. A, Left, Extracellular recordings obtained 5 min before (black trace) and 30 min after applying a HFS protocol (100
Hz, 1 s) to the DLS of WT mice (gray trace). The recordings were obtained in the presence of extracellular solutions containing [Ca 2⫹] ⫽ 1.2 mM (top panel), [Ca 2⫹] ⫽ 2.5 mM (middle panel), and
[Ca 2⫹] ⫽ 3.5 mM (bottom panel). Each trace represents the average of 20 consecutive sweeps. The shaded area represents the SEM. Right, Time course of baseline-normalized field recordings. Each
symbol represents the average of three consecutive time points. The notation “Norm PS/FV” on the y-axis refers to the amplitude ratio of the population spike and fiber volley normalized by the one
measured before applying the HFS protocol. B, As in A but for EAAC1 ⫺/⫺ mice. C, Summarized effect of HFS on the PS/FV ratio in WT mice at three different extracellular [Ca 2⫹] [1.2 mM: (n ⫽ 7)
*p ⫽ 0.047; 2.5 mM: (n ⫽ 7) p ⫽ 0.22; 3.5 mM: (n ⫽ 11) *p ⫽ 0.032]. D, Summarized effect of HFS on the PS/FV ratio in EAAC1 ⫺/⫺ mice at three different extracellular [Ca 2⫹] [1.2 mM: (n ⫽ 8)
p ⫽ 0.50; 2.5 mM: (n ⫽ 12) p ⫽ 0.28; 3.5 mM: (n ⫽ 7) p ⫽ 0.46].

this hypothesis, we measured the mRNA (Fig. 6) and protein
levels (Fig. 7) of D1R and D2R in the striatum of WT and
EAAC1 ⫺/⫺ mice, using qRT-PCR and Western blot analysis, respectively. The sensitivity of the qRT-PCR technique was validated by measuring mRNA levels for the Slc1a1 gene, encoding
EAAC1, in the striatum of WT and EAAC1 ⫺/⫺ mice (Fig. 6A–D).
We confirmed that the mRNA level of EAAC1 was negligible in
EAAC1 ⫺/⫺ mice [Fig. 6A–C; Norm Slc1a1 EAAC1 ⫺/⫺/WT:
0.05 ⫾ 0.01 (n ⫽ 5), ***p ⫽ 1.5e-7} and that the mRNA levels of
EAAC1 were similar in the DLS and VMS ( p ⫽ 0.42; Fig. 6D). The
mRNA level of D1R in the entire striatum, but not the D2R, was

significantly reduced in EAAC1 ⫺/⫺ compared with WT mice
[Norm Drd1a EAAC1 ⫺/⫺/WT: 0.65 ⫾ 0.10 (n ⫽ 11), **p ⫽
5.0e-3; Norm Drd2 EAAC1 ⫺/⫺/WT: 0.89 ⫾ 0.14 (n ⫽ 11), p ⫽
0.48; Fig. 6E–G]. Similar results were obtained when we analyzed
the DLS and VMS separately for D1R [Norm DLS Drd1a EAAC1 ⫺/⫺/
WT: 0.82 ⫾ 0.06 (n ⫽ 6), *p ⫽ 0.037; Norm VMS Drd1a
EAAC1 ⫺/⫺/WT: 0.53 ⫾ 0.08 (n ⫽ 6), **p ⫽ 1.6e-3; Fig. 6H–J]
and D2R [Norm DLS Drd2 EAAC1 ⫺/⫺/WT: 1.15 ⫾ 0.33 (n ⫽ 6),
p ⫽ 0.32; Norm VMS Drd2 EAAC1 ⫺/⫺/WT: 0.79 ⫾ 0.29 (n ⫽ 6),
p ⫽ 0.14; Fig. 6K–M], suggesting that they are widespread
throughout the entire striatal formation.
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Figure 6. mRNA levels of D1R are reduced in the DLS and VMS of EAAC1 ⫺/⫺ mice. A, Schematic representation of a coronal section of the mouse brain. The blue region defines the WT striatum,
in which the Slc1a1 gene encoding EAAC1 is abundantly expressed. B, Left, Color map representation of the Slc1a1 levels in striatal samples from WT mice (n ⫽ 5) and EAAC1 ⫺/⫺ mice (n ⫽ 5)
measured in qRT-PCR experiments. Each sample was run in triplicates (x-axis). Right, Relative amount of the Slc1a1 gene with respect to the Hprt housekeeping gene in WT and EAAC1 ⫺/⫺ mice,
measured as 2 ⫺⌬CT (**p ⫽ 1.8e-3). C, Fold change in Slc1a1 expression in EAAC1 ⫺/⫺ versus WT mice (2 ⫺⌬CT). Negligible levels of Slc1a1 (***p ⫽ 1.5e-7) are detected in EAAC1 ⫺/⫺ mice. D, Left,
Same experiments as described in B, left, performed on samples from the DLS or VMS of WT mice (n ⫽ 7). Right, As in B, right, bit for samples from (Figure legend continues.)
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Changes in D1R mRNA might be associated with altered D1R
protein expression, which we tested using Western blot analysis.
As a first step, we validated the sensitivity and specificity of the
antibodies directed against D1R and D2R. First, we performed
immunolabeling experiments on striatal sections from mice in
which the genetically encoded red fluorescent protein (RFP)
mCherry was selectively expressed either in D1- or D2-MSNs
(data not shown). In the DLS, the anti-D1R antibody labeled a
significant proportion of RFP-expressing cells in sections from
D1 Cre/⫹:Ai9 Tg/0 mice (0.70 ⫾ 0.08, n ⫽ 4) and a very small proportion of RFP-expressing cells in sections from A2A Cre/⫹:Ai9 Tg/0
mice (0.09 ⫾ 0.03, n ⫽ 3). The vast majority of immunolabeled cells
were RFP-expressing D1-MSNs (0.84 ⫾ 0.04, n ⫽ 4), not D2-MSNs
(0.13 ⫾ 0.03, n ⫽ 3). Likewise, the anti-D2R antibody labeled a
significant proportion of RFP-expressing cells in sections from
A2A Cre/⫹:Ai9 Tg/0 mice (0.83 ⫾ 0.07, n ⫽ 4) and a very small
proportion of RFP-expressing cells in sections from D1 Cre/⫹:
Ai9 Tg/0 mice (0.08 ⫾ 0.04, n ⫽ 3). The vast majority of immunolabeled cells were RFP-expressing D2-MSNs (0.89 ⫾ 0.07, n ⫽ 4),
not D1-MSNs (0.14 ⫾ 0.05, n ⫽ 3). These data showed that the
anti-D1R/D2R antibodies are sensitive and specific. To validate
their specificity in Western blot analysis, we compared the D1R
protein expression in the striatum and in the cortex, where D1R
and D2R are less abundantly expressed (Gong et al., 2003; Gong
et al., 2007) (data not shown). Accordingly, the protein expression of D1R was significantly lower in the cortex compared with
the striatum [Norm D1R striatum: 1.00 ⫾ 0.15 (n ⫽ 8), Norm
D1R cortex: 0.60 ⫾ 0.08 (n ⫽ 8), *p ⫽ 0.037]. Similar results were
obtained when using the anti-D2R antibody [Norm D2R striatum: 1.00 ⫾ 0.10 (n ⫽ 14), Norm D2R cortex: 0.69 ⫾ 0.08 (n ⫽
16), *p ⫽ 0.022]. If the antibodies used for these experiments
specifically labeled D1R or D2R bands, then these bands should no
longer be detected after preincubating the antibodies with their
corresponding control peptide antigen. Consistent with this hypothesis, no band was detected by either antibody in preadsorption experiments [Norm D1R peptide: 0.07 ⫾ 0.01 (n ⫽ 7),
***p ⫽ 3.7e-4, Norm D2R peptide: 0.13 ⫾ 0.07 (n ⫽ 7), ***p ⫽
1.1e-6]. Having confirmed the specificity of our antibodies, we
investigated whether the reduced D1R mRNA levels were associated with altered D1R protein levels in EAAC1 ⫺/⫺ mice. Consistent with the qRT-PCR data, we detected lower levels of D1R in
protein extracts from the entire striatum of EAAC1 ⫺/⫺ mice,
whereas there was no change in D2R expression [Norm D1R
4
(Figure legend continued.) the DLS and VMC. No significant difference was detected in the
expression levels of Slc1a1 between the WT DLS and VMS (p ⫽ 0.42). E, Schematic representation of a coronal section of the mouse brain in which the striatum from which we extracted the
mRNA, is highlighted in yellow. The lighter shade of yellow indicates lower Drd1a gene expression levels in EAAC1 ⫺/⫺ mice. F, Left, Color map representation of the Drd1a and Drd2 levels in
WT mice (n ⫽ 6) and EAAC1 ⫺/⫺ mice (n ⫽ 10) measured in qRT-PCR experiments. Each
sample was run in triplicate (x-axis). Right, Relative amount of the Drd1a and Drd2 gene with
respect to the Hprt housekeeping gene in WT and EAAC1 ⫺/⫺ mice, measured as 2 ⫺⌬CT.
Higher levels of Drd2 are detected in WT mice (*p ⫽ 0.011) and EAAC1 ⫺/⫺ mice (***p ⫽
9.6e-6). G, Fold change in Drd1a and Drd2 expression in EAAC1 ⫺/⫺ versus WT mice (2 ⫺⌬CT).
Reduced levels of Drd1a (**p ⫽ 5.0e-3), not Drd2 ( p ⫽ 0.48), are detected in EAAC1 ⫺/⫺ mice.
H–J, As in E–G but on samples from the DLS and VMS of WT mice (n ⫽ 7) and EAAC1 ⫺/⫺ mice
(n ⫽ 6). Lower levels of Drd1a were detected in the VMS of WT mice (*p ⫽ 0.018) and
EAAC1 ⫺/⫺ mice (***p ⫽ 7.1e-4). In the VMS, there was a significant reduction in the level of
Drd1a (*p ⫽ 0.012). A significant WT-fold change inDrd1a was detected in the DLS (*p ⫽
0.037) and VMS (**p ⫽ 1.6e-3) of EAAC1 ⫺/⫺ mice. K–M, As in E–G but for Drd2. The level of
Drd2 was lower in the VMS compared with the DLS in WT mice (n ⫽ 7, **p ⫽ 3.4e-3) and
EAAC1 ⫺/⫺ mice (n ⫽ 6, **p ⫽ 5.1e-3). No significant WT-fold change was detected in the
expression level of Drd2 in the DLS and VMS of EAAC1 ⫺/⫺ mice.
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EAAC1 ⫺/⫺/WT: 0.69 ⫾ 0.03 (n ⫽ 8), ***p ⫽ 2.7e-4; Norm D2R
EAAC1 ⫺/⫺/WT: 0.86 ⫾ 0.16 (n ⫽ 8), p ⫽ 0.51; Fig. 7A].
To determine whether the reduced of D1R protein expression
could be consequent to loss of D1-MSNs in EAAC1 ⫺/⫺ mice, we
compared the proportion and density of RFP-expressing cells in
D1 Cre/⫹:Ai9 Tg/0 and D1 Cre/⫹:Ai9 Tg/0:EAAC1 ⫺/⫺ mice, D1 tdTomato/⫹
and D1 tdTomato/⫹:EAAC1 ⫺/⫺ mice, and A2A Cre/⫹:Ai9 Tg/0 and
A2A Cre/⫹:Ai9 Tg/0:EAAC1 ⫺/⫺ mice (data not shown). The proportion of RFP-expressing cells was calculated as the ratio between red cells (expressing RFPs) and blue cells (labeled with
DAPI), whereas the density of RFP-expressing cells was calculated as the number of red cells in the matrix region of the DLS.
There was no significant difference in the density of RFPexpressing D1-MSNs in WT and EAAC1 ⫺/⫺ mice, in the DLS
[WT: 0.81e-3 ⫾ 7.10e-5 m ⫺2 (n ⫽ 11), EAAC1 ⫺/⫺ 0.83e-3 ⫾
0.12e-3 m ⫺2 (n ⫽ 6), p ⫽ 0.90] and VMS [WT: 0.69e-3 ⫾
0.11e-3 m ⫺2 (n ⫽ 6), EAAC1 ⫺/⫺ 0.99e-3 ⫾ 8.15e-5 m ⫺2 (n ⫽
6), p ⫽ 0.073]. The proportion of D1-MSNs was also similar in
WT and EAAC1 ⫺/⫺ mice in the DLS [WT: 0.39 ⫾ 0.03 (n ⫽ 11),
EAAC1 ⫺/⫺: 0.41 ⫾ 0.03 (n ⫽ 6), p ⫽ 0.64] and VMS [WT: 0.31 ⫾
0.06 (n ⫽ 7), EAAC1 ⫺/⫺: 0.45 ⫾ 0.02 (n ⫽ 6), p ⫽ 0.055]. Similar
results were obtained when measuring the density of RFPexpressing D2-MSNs in the presence and absence of EAAC1, in
the DLS [WT: 1.12e-3 ⫾ 3.78e-5 m ⫺2 (n ⫽ 6), EAAC1 ⫺/⫺
1.07e-3 ⫾ 5.94e-5 m ⫺2 (n ⫽ 5), p ⫽ 0.14] and VMS [WT:
0.89e-3 ⫾ 3.38e-5 m ⫺2 (n ⫽ 6), EAAC1 ⫺/⫺ 0.86e-3 ⫾ 2.61e-5
m ⫺2 (n ⫽ 5), p ⫽ 0.58]. The density of D2-MSNs was larger in
the DLS than in the VMS, but this difference was present in both
WT mice [WT DLS: 1.2e-3 ⫾ 3.8e-5 (n ⫽ 6), VMS: 3.9e-4 ⫾
3.4e-5 (n ⫽ 6), **p ⫽ 1.7e-4] and EAAC1 ⫺/⫺ mice [EAAC1 ⫺/⫺
DLS: 1.1e-3 ⫾ 5.9e-5 (n ⫽ 5), VMS: 0.9e-3 ⫾ 2.6e-5 (n ⫽ 5), *p ⫽
0.022] and the proportion of D2-MSNs was also similar in WT
and EAAC1 ⫺/⫺ mice in the DLS [WT: 0.40 ⫾ 0.01 (n ⫽ 6),
EAAC1 ⫺/⫺: 0.40 ⫾ 0.02 (n ⫽ 5), p ⫽ 0.93] and VMS [WT: 0.38 ⫾
0.02 (n ⫽ 6), EAAC1 ⫺/⫺: 0.40 ⫾ 0.01 (n ⫽ 5), p ⫽ 0.31]. Together, these results suggest that loss of EAAC1 is not associated
with altered density of D1- or D2-MSNs. Therefore, the reduced
D1R expression in EAAC1 ⫺/⫺ mice might be due to altered trafficking and internalization of D1R from the cell membrane.
The expression of dopamine receptors is subject to intracellular regulation by a variety of signaling molecules including the
phosphoprotein DARPP-32, which has been suggested to act as a
robust integrator of glutamatergic and dopaminergic transmission (Gould and Manji, 2005; Fernandez et al., 2006). Although
the total level of DARPP-32 was similar in WT and EAAC1 ⫺/⫺
mice [Norm DARPP-32 EAAC1 ⫺/⫺/WT: 1.00 ⫾ 0.05 (n ⫽ 12),
p ⫽ 0.92; Fig. 7B], the ability of this protein to modulate dopaminergic and glutamatergic signaling depends, not only on its
abundance, but also on its phosphorylation state (Greengard et
al., 1999). The signaling cascades that modulate the phosphorylation state of DARPP-32 include the Gq signaling cascades activated by mGluRI (Liu et al., 2001; Liu et al., 2002; Svenningsson et
al., 2004; Nishi et al., 2005). Of the four known phosphorylation
sites of DARPP-32 (T34, T75, S97, and S130), the only one differentially phosphorylated in EAAC1 ⫺/⫺ mice was pDARPP32 S130 [pDARPP-32 S130 WT: 0.28 ⫾ 0.08 (n ⫽ 14), EAAC1 ⫺/⫺:
0.60 ⫾ 0.10 (n ⫽ 17), *p ⫽ 0.024; Fig. 7C]. The almost threefold
increase in pDARPP-32 S130 phosphorylation indicates that the
phosphorylation pattern of pDARPP-32 is profoundly disrupted
in the absence of EAAC1 [Norm pDARPP-32 S130 EAAC1 ⫺/⫺/
WT: 2.70 ⫾ 0.44 (n ⫽ 14), **p ⫽ 2.1e-3; Fig. 7 D, E].
Is it plausible that changes in signaling pathways coupled to
mGluRI, known to activate phospholipase C, to stimulate the
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generation of inositol 1,4,5-trisphosphate,
and to mobilize calcium from internal
stores (Casabona et al., 1997), would increase pDARPP-32 S130 phosphorylation?
We addressed this question using a modeling approach based on 3D reaction– diffusion Monte Carlo simulations of
calcium diffusion and DARPP-32 phosphorylation (Fig. 8). We modeled the geometry of the postsynaptic terminal as a 1
m 3 sphere, consistent with the average
volume of spine heads of striatal neurons
(Forlano and Woolley, 2010). At the beginning of each simulation, the sphere
contained 3000 DARPP-32 molecules and
a number of protein kinases and phosphatases known to modulate the phosphorylation state of DARPP-32 (Table 6). We
then allowed the system to equilibrate for
150 s. Under these baseline conditions,
the resting concentration of pDARPP32S 130 was 10 nM. We then released variable amounts of calcium (1 M–1 mM)
from the center of the sphere to simulate
the intracellular calcium rise coupled to
mGluRI activation. Single pulses or trains
of 10 pulses (0.1–10 Hz) evoked a detectable increase pDARPP-32 S130, suggesting
that the altered activation of Gq signaling
pathways coupled to mGluRI and the
consequent increase in intracellular calcium concentration can alter pDARPP32 S130 phosphorylation.
EAAC1 controls plasticity and
dopamine receptor expression via
signaling pathways coupled to
mGluRI activation
If the loss of synaptic plasticity (Fig. 5),
reduced D1R expression (Figs. 6, 7A), altered phosphorylation of DARPP-32 (Fig.
7B–E), and disrupted grooming behaviors
in EAAC1 ⫺/⫺ mice (Fig. 3) were all triggered by increased mGluRI activation
4

Figure 7. Reduced expression of D1R in EAAC1 ⫺/⫺ mice is associated with altered phosphorylation of DARPP-32. A, Western
blots for D1R, D2R, and ␤-actin in WT mice (n ⫽ 11) and EAAC1 ⫺/⫺ mice (n ⫽ 8) show decreased levels of D1R (***p ⫽ 2.7e-4),
not D2R ( p ⫽ 0.51), in EAAC1 ⫺/⫺ mice. B, Western blot analysis for DARPP-32 showing no significant difference in its expression
between WT mice (n ⫽ 15) and EAAC1 ⫺/⫺ mice (n ⫽ 12, p ⫽ 0.92). C, Western blot analysis for pDARPP-32 T34 [WT mice

(n ⫽ 10), EAAC1 ⫺/⫺ mice (n ⫽ 10), p ⫽ 0.41), pDARPP32 T75 (WT mice (n ⫽ 13), EAAC1 ⫺/⫺ mice (n ⫽ 14), p ⫽
0.84), pDARPP-32 S97 (WT mice (n ⫽ 13), EAAC1 ⫺/⫺ mice
(n ⫽ 13), p ⫽ 0.98), pDARPP-32 S130 (WT mice (n ⫽ 14),
EAAC1 ⫺/⫺ mice (n ⫽ 17), *p ⫽ 0.024]. D, Pie chart representation of the phosphorylation distribution on the T34, T75,
S97, and S130 sites of DARPP-32. The red curve highlights the
S130 site, which shows increased phosphorylation in
EAAC1 ⫺/⫺ mice. E, As in C but after data normalization by the
average band intensity values measured in WT mice [pDARPP32 T34 WT mice (n ⫽ 10), EAAC1 ⫺/⫺ mice (n ⫽ 10), p ⫽
0.46; pDARPP-32 T75 WT mice (n ⫽ 13), EAAC1 ⫺/⫺ mice
(n ⫽ 14), p ⫽ 0.72; pDARPP-32 S97 WT mice (n ⫽ 13),
EAAC1 ⫺/⫺ mice (n ⫽ 13), p ⫽ 0.89; pDARPP-32 S130 WT
mice (n ⫽ 14), EAAC1 ⫺/⫺ mice (n ⫽ 15), **p ⫽ 2.1e-3].
Data in A, B, and E represent the band intensity ratio between
the target protein and ␤-actin in samples from WT versus
EAAC1 ⫺/⫺ mice in the same blotting membrane.

954 • J. Neurosci., January 24, 2018 • 38(4):937–961

Bellini et al. • Neuronal Transporters Control Compulsive Behaviors

(Fig. 4), then we would expect to convert
the functional phenotype of EAAC1 ⫺/⫺
into that of WT mice by blocking mGluRI.
Consistent with this hypothesis, blocking
mGluRI with LY367385 (50 M) and
MPEP (10 M) rescued LTP and LTD in
EAAC1 ⫺/⫺ mice [Norm PS/FV amp
[Ca 2⫹]o ⫽ 1.2 mM: 1.28 ⫾ 0.11 (n ⫽ 22),
*p ⫽ 0.015; Norm PS/FV amp [Ca 2⫹]o ⫽
2.5 mM: 1.08 ⫾ 0.08 (n ⫽ 12), p ⫽ 0.36;
Norm PS/FV amp [Ca 2⫹]o ⫽ 3.5 mM:
0.84 ⫾ 0.05 (n ⫽ 8), *p ⫽ 0.018; Fig. 9].
This pharmacological treatment also rescued D1R expression [Norm D1R
EAAC1 ⫺/⫺: 1.13 ⫾ 0.13 (n ⫽ 9), p ⫽ 0.35;
Norm D2R EAAC1 ⫺/⫺: 1.33 ⫾ 0.14 (n ⫽
7), p ⫽ 0.06; Fig. 10A] and reduced
pDARPP-32 S130 phosphorylation [Norm
pDARPP-32 S130 EAAC1 ⫺/⫺/WT: 0.37 ⫾
0.11 (n ⫽ 9), ***p ⫽ 2.1e-4; Fig. 10C–E].
These findings are consistent with an effect of mGluRI on pDARPP-32 S130 phosphorylation (Liu et al., 2001; Liu et al.,
2002). However, this broad pharmacological approach also induced a significant
reduction in the total level of DARPP-32
[Norm DARPP-32: 0.87 ⫾ 0.04 (n ⫽ 9),
*p ⫽ 0.029; Fig. 10B] and a decrease in
pDARPP-32 T75–phosphorylation [Norm
pDARPP-32 T75 EAAC1 ⫺/⫺/WT: 0.45 ⫾
0.05 (n ⫽ 12), ***p ⫽ 1.0e-5; Fig. 10C–E].
These effects were not detected in
EAAC1 ⫺/⫺ mice (Fig. 7) and may be consequent to the widespread blockade of
mGluRI in multiple regions of the brain
still present in slice preparations. For this
reason, we felt compelled to test more specific approaches that could recapitulate
more faithfully the molecular and behavioral phenotype of EAAC1 ⫺/⫺ mice.
Activation of signaling pathways
coupled to mGluRI recapitulates the
molecular and behavioral phenotype of
EAAC1 ⴚ/ⴚ mice in WT mice
In the striatum, mGluRI are expressed
in both D1- and D2-MSNs (TallaksenGreene et al., 1998). The observed reduction of D1R expression in EAAC1 ⫺/⫺
mice (Fig. 7A), however, suggests a higher
sensitivity to mGluRI activation in D1MSNs compared with D2-MSNs. If this
were true, then we would expect cell-specific activation of G-protein-coupled signaling cascades activated by mGluRI in
D1-MSNs to mimic closely the molecular
and behavioral phenotype of EAAC1 ⫺/⫺
mice. This hypothesis can be tested using a
chemogenetic approach based on the
combined use of BAC transgenic mouse
lines and Designer Receptors Exclusively
Activated by Designer Drugs (DREADDs)
(Armbruster et al., 2007). The conditional

Figure 8. Modeling the effect of Gq signaling cascade activation on DARPP-32 phosphorylation. A–C, Snapshots showing the
effect of different patterns of intracellular calcium rise (yellow) on the total concentration of DARPP-32 (magenta) and of pDARPP32 S130 (green). D, Time course of intracellular calcium concentration evoked by single (left) or 10 pulse trains of intracellular
calcium rise at 1 Hz (middle) and 0.1 Hz (right). Darker colors correspond to higher intracellular calcium concentrations. E, Relative
change in intracellular pDARPP-32 S130. Darker colors correspond to the changes evoked by higher intracellular calcium concentration. F, Summary graph of the change in the peak pDARPP-32 S130 concentration evoked by increasing concentrations (x-axis) and
different patterns of intracellular calcium rise (left to right). Transient increase in the intracellular calcium concentration cause a
substantial increase in the intracellular pDARPP-32 S130 concentration.
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Figure 9. Blocking mGluRI activation rescues the Ca 2⫹ dependence of long-term plasticity
in EAAC1 ⫺/⫺ mice. A, Left, Extracellular recordings performed in the presence of the mGluRI
blockers LY367385 (50 M) and MPEP (10 M) obtained 5 min before (red trace) and 30 min
after applying an HFS protocol (100 Hz, 1 s) to the DLS of EAAC1 ⫺/⫺ mice (pink trace). The
recordings were obtained in the presence of extracellular solutions containing [Ca 2⫹] ⫽ 1.2
mM. Each trace represents the average of 20 consecutive sweeps. The shaded area represents
the SEM. Right, Time course of baseline-normalized field recordings. Each symbol represents
the average of three consecutive time points. The notation “Norm PS/FV” on the y-axis refers
to the amplitude ratio of the population spike and fiber volley normalized by the one measured
before applying the HFS protocol. B, As in A but in the presence of extracellular solutions
containing [Ca 2⫹] ⫽ 2.5 mM. C, As in A but in the presence of extracellular solutions containing
[Ca 2⫹] ⫽ 3.5 mM. D, Summarized effect of HFS on the PS/FV ratio in EAAC1 ⫺/⫺ mice in the
presence of mGluRI blockers and at three different extracellular [Ca 2⫹] [1.2 mM (n ⫽ 22), *p ⫽
0.015; 2.5 mM (n ⫽ 12), p ⫽ 0.36; 3.5 mM (n ⫽ 8), *p ⫽ 0.018].

expression of DREADDS in D1 Cre/⫹ mice allowed us to activate
Gq signaling cascades like those coupled to mGluRI exclusively in
D1-MSNs. To accomplish this goal, we performed unilateral stereotaxic injections of AAV-hSyn-DIO-hM3D(Gq)-mCherry in
the DLS of D1 Cre/⫹ mice aged P14 –P16 (Fig. 11, left). We confirmed the successful DREADD transfection of the injected striatum by measuring the expression of the mCherry protein in the
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striatum and cortex of the injected and noninjected brain. The
noninjected striatum and the adjacent cortex were not expected
to express mCherry and were used as internal controls to confirm
the accuracy of the stereotaxic injections in the DLS, not in the
adjacent cortex. One week after the surgery, the mice were habituated to daily intraperitoneal saline injections to prevent any bias
of our results due to acute stress responses to the intraperitoneal
injections of the DREADD activator CNO 2 weeks after surgery.
DREADD activation is maximal 1–1.5 h after the CNO injection
and starts declining after 3 h (Gomez et al., 2017; Raper et al.,
2017). Therefore, any effect of CNO is likely to happen within this
time window. One hour after the CNO injections, we video monitored the mice to measure their grooming activity and then killed
them 2 h after the CNO injection to extract the striatum for
Western blot analysis (Fig. 11A). We then measured the protein
levels of mCherry, D1R, D2R, and pDARPP-32 and compared
their expression levels in the injected and noninjected striatum
and cortex (Fig. 11B–D, left). We detected a substantial increase
in mCherry expression only in the injected striatum of D1 Cre/⫹
mice, not in the adjacent cortex, confirming the accuracy of our
stereotaxic injections [hM3D(Gq) cortex: 1.22 ⫾ 0.20 (n ⫽ 10),
p ⫽ 0.28; hM3D(Gq) striatum: 2.89 ⫾ 0.80 (n ⫽ 10), *p ⫽ 0.040;
Fig. 11B, left]. DREADD-mediated activation of Gq signaling
cascades led to reduced D1R expression [hM3D(Gq): 0.79 ⫾ 0.07
(n ⫽ 9), *p ⫽ 0.013] without affecting D2R expression
[hM3D(Gq): 0.91 ⫾ 0.10 (n ⫽ 8), p ⫽ 0.35; Fig. 11C, left]. Gq
signaling activation in D1-MSNs also caused a significant and
specific increase in the phosphorylation of pDARPP-32 S130 in
D1 Cre/⫹ mice [hM3D(Gq): 2.48 ⫾ 0.49 (n ⫽ 11), **p ⫽ 5.6e-3;
Fig. 11D, left]. These results show that D1-MSN, cell-specific
activation of Gq signaling cascades like the ones activated by
mGluRI can lead to increased phosphorylation of pDARPP32 S130 and reduced D1R expression similar to what we observed in EAAC1 ⫺/⫺ mice, possibly because of increased D1R
internalization.
As an additional test of our hypothesis, we performed stereotaxic injections of AAV-hSyn-DIO-hM3D(Gq)-mCherry in the
DLS of A2A Cre/⫹ mice. We confirmed the increase in mCherry
expression in the injected striatum and not in the adjacent cortex
in A2A Cre/⫹ mice [hM3D(Gq) cortex: 1.18 ⫾ 0.31 (n ⫽ 8), p ⫽
0.59; hM3D(Gq) striatum: 2.06 ⫾ 0.52 (n ⫽ 23), *p ⫽ 0.035; Fig.
11B, right]. DREADD-mediated activation of Gq signaling cascades in D2-MSNs did not alter D1R expression [hM3D(Gq):
1.10 ⫾ 0.15 (n ⫽ 9), p ⫽ 0.63] and D2R expression [hM3D(Gq):
0.78 ⫾ 0.20 (n ⫽ 5), p ⫽ 0.34; Fig. 11C, right] and did not cause
any significant change in the phosphorylation of pDARPP-32 S130
[hM3D(Gq): 1.04 ⫾ 0.32 (n ⫽ 6), p ⫽ 0.89; Fig. 11D, right].
These results showed that activation of Gq signaling cascades in
D2-MSNs does not induce any of the changes in D1R expression
and pDARPP-32phosphorylation detected in EAAC1 ⫺/⫺ mice.
If the cell-specific activation of Gq signaling cascades in D1MSNs recapitulates the molecular phenotype of EAAC1 ⫺/⫺
mice, then does it also reproduce the behavioral phenotype of
EAAC1 ⫺/⫺ mice? To address this question, we repeated our
grooming analysis in DREADD-injected D1 Cre/⫹ and A2A Cre/⫹
mice (Fig. 11 E, F ). As a control, to rule out potential off-target
effects of CNO or its metabolites on endogenous receptors (Gomez et al., 2017), we performed stereotaxic injections of the
DREADD construct or of saline solution and intraperitoneal
CNO injections on age-matched WT mice (here referred to as
sham; Fig. 11 E, F ). Gq signaling activation caused an increase in
the grooming frequency in D1 Cre/⫹ mice versus sham mice
[sham: 5.3 ⫾ 0.4e-3 Hz (n ⫽ 25); D1 Cre/⫹: 8.0 ⫾ 0.8e-3 Hz (n ⫽
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39); D1 Cre/⫹ vs sham: **p ⫽ 6.0e-3; Fig. 11 E, F] without changing
the duration of grooming episodes [sham: 32.2 ⫾ 4.2 s (n ⫽ 34);
D1 Cre/⫹: 40.9 ⫾ 3.5 s (n ⫽ 44), p ⫽ 0.12; Fig. 11 E, F]. Gq signaling
activation in the DLS of A2A Cre/⫹ mice did not alter the grooming frequency or duration [6.0 ⫾ 0.4e-3 Hz (n ⫽ 49), p ⫽ 0.28;
42.3 ⫾ 3.9 s (n ⫽ 58), p ⫽ 0.08; Fig. 11 E, F]. The grooming
behavior of D1 Cre/⫹ mice that received DREADD activation was
reminiscent of that of EAAC1 ⫺/⫺ mice, whereas the behavior of
A2A Cre/⫹ mice was similar to that of WT mice shown in Figure 3,
A and B. Therefore, cell-specific activation of Gq signaling cascades in D1-MSNs recapitulates the molecular and behavioral
phenotype of EAAC1 ⫺/⫺ mice. These findings identify EAAC1 as
a key regulator of glutamatergic and dopaminergic transmission
and of repeated motor behaviors.

Discussion
Glutamate transporters play a fundamental role in shaping excitatory synaptic transmission in the brain. This knowledge largely
relies on numerous and detailed studies of glial transporters that
are abundantly expressed in the neuropil (Danbolt, 2001). The
neuronal glutamate transporter EAAC1 accounts for a small fraction of all glutamate transporters in the brain (Holmseth et al.,
2012). Therefore, its functional role has long remained enigmatic
(Scimemi et al., 2009; Holmseth et al., 2012) despite evidence of a
genetic association between polymorphisms in the gene encoding
EAAC1 and OCD (Dickel et al., 2006; Porton et al., 2013; Zike et
al., 2017). In the hippocampus, EAAC1 limits extrasynaptic GluN
activation by rapidly binding synaptically released glutamate
(Scimemi et al., 2009). The striatum is one of the brain regions
where EAAC1 is most abundantly expressed (Danbolt, 2001; Kanai and Hediger, 2004) and is part of a polysynaptic circuit that
shows patterns of hyperactivity in patients with OCD (Ting and
Feng, 2011; Ahmari et al., 2013). In the striatum, excitatory synaptic transmission is largely mediated by GluA receptors, with
very little involvement of GluN receptors (Sung et al., 2001).
mGluRI glutamate receptors are abundantly expressed in the
striatum (Albin et al., 1992; Shigemoto et al., 1992; Shigemoto et
al., 1993; Testa et al., 1998; Ferraguti and Shigemoto, 2006) and
their activation is crucial for the induction of long-term synaptic
plasticity (Calabresi et al., 1992b; Anwyl, 1999; Sung et al., 2001).
Small changes in the excitatory drive onto distinct populations of
striatal neurons is important in the context of OCD because they
can exert a powerful control of the dynamics of neuronal circuits
that are dysfunctional in OCD (Klaus and Plenz, 2016; O’Donnell
et al., 2017; Rădulescu et al., 2017).
Here, we show that EAAC1 limits mGluRI activation in the
striatum. By limiting mGluRI activation, EAAC1 promotes D1R
expression and long-term plasticity. An interesting implication of
4

Figure 10. Blocking mGluRI activation rescues D1R expression and alters the phosphorylation pattern of DARPP-32. A, Western blots for D1R, D2R, and ␤-actin in the presence of the
mGluRI blockers LY367385 (50 M) and MPEP (10 M) show no significant difference in the
expression of D1R and D2R [D1R: WT mice (n ⫽ 9), EAAC1 ⫺/⫺ mice (n ⫽ 9), p ⫽ 0.35; D2R: WT
mice (n ⫽ 7), EAAC1 ⫺/⫺ mice (n ⫽ 7), p ⫽ 0.064]. B, mGluRI blockade induces a slight
reduction in DARPP-32 expression between WT mice (n ⫽ 9) and EAAC1 ⫺/⫺ mice (n ⫽ 9)

(*p ⫽ 0.029). C, Western blot analysis for pDARPP-32 T34 [WT mice (n ⫽ 5), EAAC1 ⫺/⫺ mice
(n ⫽ 6), p ⫽ 0.98], pDARPP-32 T75 [WT mice (n ⫽ 6), EAAC1 ⫺/⫺ mice (n ⫽ 7), *p ⫽ 0.017],
pDARPP-32 S97 [WT mice (n ⫽ 9), EAAC1 ⫺/⫺ mice (n ⫽ 9), p ⫽ 0.34], and pDARPP-32 S130
[WT mice (n ⫽ 12), EAAC1 ⫺/⫺ mice (n ⫽ 9), **p ⫽ 4.6e-3]. D, Pie chart representation of the
phosphorylation distribution on the T34, T75, S97, and S130 sites of DARPP-32 in the presence
of mGluRI blockers. The red curves highlight the T75 and S130 site, which show reduced phosphorylation in EAAC1 ⫺/⫺ mice. E, As in C but after data normalization by the average band
intensity values measured in WT mice [WT mice (n ⫽ 5), EAAC1 ⫺/⫺ mice (n ⫽ 6), p ⫽ 0.62],
pDARPP-32 T75 [WT mice (n ⫽ 9), EAAC1 ⫺/⫺ mice (n ⫽ 7), ***p ⫽ 1.0e-5], pDARPP-32 S97
[WT mice (n ⫽ 9), EAAC1 ⫺/⫺ mice (n ⫽ 9), p ⫽ 0.16], and pDARPP-32 S130 [WT mice (n ⫽
12), EAAC1 ⫺/⫺ mice (n ⫽ 9), ***p ⫽ 2.1e-4]. Data in A, B, and E represent the band intensity
ratio between the target protein and ␤-actin measured in samples from EAAC1 ⫺/⫺ mice and
normalized by analogous measures in samples from WT mice blotted in the same membrane.
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Figure 11. Cell-specific activation of Gq signaling pathway induces decreased D1R expression and increased pDARPP-32 S130 phosphorylation. A, Timeline of the experimental design. At
P14 –P16, mice received a unilateral stereotaxic injection of hM3D(Gq). After 1 week, they started receiving daily intraperitoneal saline injections. At P28 –P30, they received intraperitoneal
injections of CNO (5 mg/kg). One hour after the CNO injections, they were video-monitored to examine their grooming behavior. Two hours after the CNO injections, they were killed. Proteins for
Western blot analysis were extracted from the control and injected striatum and from the adjacent cortices. B, Left, mCherry expression in D1 Cre/⫹ mice. (Figure legend continues.)
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our work is that intracellular Gq signaling cascades coupled to
mGluRI activation are able to regulate both D1R expression and
the phosphorylation state of DARPP-32 rapidly, within a 2 h time
window (Fig. 11). These findings are consistent with evidence showing that D1R internalization from the cell membrane can be modified within minutes using different pharmacological manipulations
(Dumartin et al., 1998; Rassu et al., 2017).
An important insight of our work is that the functional role of
EAAC1 differs across brain regions and therefore cannot rely
exclusively on previous work in the hippocampus (Scimemi et al.,
2009). Not only are there regional differences in the density of
expression of EAAC1, but there are also regional differences in
the distribution of other molecules susceptible to the activity of
EAAC1 (e.g., GluN and mGluRI). The distinctive neuronal localization of EAAC1 puts it at an important positional advantage
with respect to glial glutamate transporters, allowing it to be the
first transporter to bind glutamate as it diffuses out of the synaptic cleft. Although previous work hypothesized that loss of
EAAC1 may lead to increased glutamate concentration in the
CSF (Chakrabarty et al., 2005; Porton et al., 2013), our experimental and modeling data suggest that this is an unlikely scenario
mainly because the expression of EAAC1 is significantly lower
than that of glial glutamate transporters (Holmseth et al., 2012).
In the striatum and hippocampus, EAAC1 is not implicated in the
regulation of the steady-state ambient glutamate concentration,
but rather in the control of phasic synaptic transmission and
long-term plasticity.
The findings that EAAC1 ⫺/⫺ mice show reduced D1R expression is consistent with recent radiolabeling assays showing decreased D1R density in the DLS of mice with constitutively
reduced EAAC1 expression via prolonged exposure to amphetamine (Zike et al., 2017). The DARPP-32 phosphoprotein is
abundantly but not exclusively expressed in D1-MSNs (Ouimet
et al., 1984; Anderson and Reiner, 1991) and is known to integrate glutamatergic and dopaminergic transmission in the striatum (Svenningsson et al., 2004). Our findings do not allow us to
distinguish whether the effect of EAAC1 on D1R expression is
mediated directly by DARPP-32 or by other molecules that are
part of the Gq signaling cascades activated by mGluRI. However,
they raise the possibility that these intracellular mechanisms may
have different functional implications for integrating glutamatergic and dopaminergic signals in D1- and D2-MSNs.
4
(Figure legend continued.) A significant increase in mCherry expression was detected only in the
striatum of D1 Cre/⫹ mice (n ⫽ 10, *p ⫽ 0.040). Right, mCherry expression in A2A Cre/⫹ mice.
A significant increase in mCherry expression was detected only in the striatum of A2A Cre/⫹ mice
(n ⫽ 23, *p ⫽ 0.035). C, Left, D1R and D2R expression in D1 Cre/⫹ mice (D1R: n ⫽ 9, *p ⫽
0.013; D2R: n ⫽ 8, p ⫽ 0.35). The expression of D1R is significantly reduced in the injected
striatum. Right, D1R and D2R expression in A2A Cre/⫹ mice (D1R: n ⫽ 9, p ⫽ 0.63; D2R: n ⫽ 5,
p ⫽ 0.34). The expression of D1R and D2R is similar in the injected and noninjected striatum.
D, Left, hM3D(Gq) injection in D1 Cre/⫹ mice leads to increased pDARPP-32 S130 [pDARPP-32 T34
(n ⫽ 10), p ⫽ 0.92]; pDARPP-32 T75 (n ⫽ 11), p ⫽ 0.18; pDARPP-32 S97 (n ⫽ 11), p ⫽ 0.13,
pDARPP-32 S130 (n ⫽ 11), **p ⫽ 5.6e-3). Right, hM3D(Gq) injection in A2A Cre/⫹ mice leads to
no change in pDARPP-32 [pDARPP-32 T34 (n ⫽ 9), p ⫽ 0.75; pDARPP-32 T75 (n ⫽ 8), p ⫽ 0.84;
pDARPP-32 S97 (n ⫽ 8), p ⫽ 0.31; pDARPP-32 S130 (n ⫽ 6), p ⫽ 0.89]. E, Summary of the
frequency [frequency: sham (n ⫽ 25), D1 Cre/⫹ (n ⫽ 39), sham vs D1 Cre/⫹ **p ⫽ 6.0e-3,
A2A Cre/⫹ (n ⫽ 49), sham vs A2A Cre/⫹ p ⫽ 0.28] and duration of grooming episodes in sham
and D1 Cre/⫹ mice injected with hM3D(Gq) [duration: sham (n ⫽ 34), D1 Cre/⫹ (n ⫽ 44), sham
vs D1 Cre/⫹ p ⫽ 0.12, A2A Cre/⫹ (n ⫽ 58), sham vs A2A Cre/⫹ p ⫽ 0.08]. F, Relationship
between the frequency and duration of grooming episodes in sham (left), D1 Cre/⫹ (middle),
and A2A Cre/⫹ mice (right). The inset represents a density plot of the data, with blue areas
corresponding to the duration and frequency of the most commonly observed grooming
episodes.

Although many of the effects described here may appear subtle,
they are noteworthy, not only because they are statistically robust,
but alaso because they yield novel insights into the physiological and
pathological implications of EAAC1 for neuropsychiatric disorders
that still lack effective pharmacological treatments. Loss of EAAC1 is
associated with a distinctive behavioral phenotype, which includes increased anxiety-like and disrupted grooming behaviors.
The altered motor behaviors of EAAC1 ⫺/⫺ mice can be recapitulated by cell-specific activation of mGluRI-activated signaling
cascades in D1-MSNs. The finding that increased mGluRI activation contributes to increased anxiety-like behaviors and repeated movement execution in EAAC1 ⫺/⫺ mice is consistent
with a key role for these neuronal glutamate transporters in the
modulation of motor function and perseverative behaviors. Our
data are consistent with previous work in Sapap3 knock-out
mice, in which increased mGluRI activation drives OCD-like behaviors via disruption of mGluR5-Homer interaction and constitutive mGluR5 signaling (Wan et al., 2011; Ade et al., 2016).
Interestingly, PET studies in humans show that the mGluRI distribution volume ratio in brain regions that show functional abnormalities in OCD (e.g., the corticostriatal-thalamo-cortical
pathway) is positively correlated with the patients’ Y-BOCS obsession scores (Akkus et al., 2014). Increased expression and activation of mGluRI has also been observed in patients affected by
other types of autism spectrum disorders (e.g., fragile X syndrome, tuberous sclerosis complex) and intellectual disability
(Boer et al., 2008; Maccarrone et al., 2010; Lohith et al., 2013),
suggesting a possible common etiology for a broad range of neuropsychiatric diseases (D’Antoni et al., 2014). Currently, many
patients diagnosed with OCD are treated with cognitive behavioral therapy and/or serotonin reuptake inhibitors, but these approaches do not improve the symptoms of the disease for ⬃50%
of the patients (Dougherty et al., 2004; Koran et al., 2007). One
important implication of our work is that the treatment of neuropsychiatric disorders such as OCD may be particularly challenging because it may require either cell-specific targeting of
mGluRI or pharmacological manipulations that affect both glutamatergic and dopaminergic transmission in specific regions of
the brain.
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Dumartin B, Caillé I, Gonon F, Bloch B (1998) Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by
dopamine agonists. J Neurosci 18:1650 –1661. Medline
Fernandez E, Schiappa R, Girault JA, Le Novère N (2006) DARPP-32 is a
robust integrator of dopamine and glutamate signals. PLoS Comput Biol
2:e176. CrossRef Medline
Ferraguti F, Shigemoto R (2006) Metabotropic glutamate receptors. Cell
Tissue Res 326:483–504. CrossRef Medline
Feusner JD, Hembacher E, Phillips KA (2009) The mouse who couldn’t stop
washing: pathologic grooming in animals and humans. CNS Spectr 14:
503–513. CrossRef Medline

J. Neurosci., January 24, 2018 • 38(4):937–961 • 959
Forlano PM, Woolley CS (2010) Quantitative analysis of pre- and postsynaptic sex differences in the nucleus accumbens. J Comp Neurol 518:1330 –
1348. CrossRef Medline
Furuta A, Rothstein JD, Martin LJ (1997) Glutamate transporter protein
subtypes are expressed differentially during rat CNS development. J Neurosci 17:8363– 8375. Medline
Gomez JL, Bonaventura J, Lesniak W, Mathews WB, Sysa-Shah P, Rodriguez
LA, Ellis RJ, Richie CT, Harvey BK, Dannals RF, Pomper MG, Bonci A,
Michaelides M (2017) Chemogenetics revealed: DREADD occupancy
and activation via converted clozapine. Science 357:503–507. CrossRef
Medline
Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak
NJ, Joyner A, Leblanc G, Hatten ME, Heintz N (2003) A gene expression
atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425:917–925. CrossRef Medline
Gong S, Doughty M, Harbaugh CR, Cummins A, Hatten ME, Heintz N,
Gerfen CR (2007) Targeting Cre recombinase to specific neuron populations with bacterial artificial chromosome constructs. J Neurosci 27:
9817–9823. CrossRef Medline
Goubard V, Fino E, Venance L (2011) Contribution of astrocytic glutamate
and GABA uptake to corticostriatal information processing. J Physiol
589:2301–2319. CrossRef Medline
Gould TD, Manji HK (2005) DARPP-32: A molecular switch at the nexus of
reward pathway plasticity. Proc Natl Acad Sci U S A 102:253–254. CrossRef
Medline
Greengard P, Allen PB, Nairn AC (1999) Beyond the dopamine receptor:
the DARPP-32/protein phosphatase-1 cascade. Neuron 23:435– 447.
CrossRef Medline
Gubellini P, Saulle E, Centonze D, Bonsi P, Pisani A, Bernardi G, Conquet F,
Calabresi P (2001) Selective involvement of mGlu1 receptors in corticostriatal LTD. Neuropharmacology 40:839 – 846. CrossRef Medline
Hanna GL, Veenstra-VanderWeele J, Cox NJ, Boehnke M, Himle JA, Curtis
GC, Leventhal BL, Cook EH Jr (2002) Genome-wide linkage analysis of
families with obsessive-compulsive disorder ascertained through pediatric probands. Am J Med Genet 114:541–552. CrossRef Medline
Hattori T, McGeer PL (1973) Synaptogenesis in the corpus striatum of infant rat. Exp Neurol 38:70 –79. CrossRef Medline
Holmseth S, Dehnes Y, Huang YH, Follin-Arbelet VV, Grutle NJ, Mylonakou
MN, Plachez C, Zhou Y, Furness DN, Bergles DE, Lehre KP, Danbolt NC
(2012) The density of EAAC1 (EAAT3) glutamate transporters expressed
by neurons in the mammalian CNS. J Neurosci 32:6000 – 6013. CrossRef
Medline
Ikeda SR, Lovinger DM, McCool BA, Lewis DL (1995) Heterologous expression of metabotropic glutamate receptors in adult rat sympathetic
neurons: subtype-specific coupling to ion channels. Neuron 14:1029 –
1038. CrossRef Medline
Jabaudon D, Shimamoto K, Yasuda-Kamatani Y, Scanziani M, Gähwiler BH,
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